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To date, perfluorocarbon particles have been most commonly studied in 
conjunction with ultrasound imaging, and as liquid ventilators due to their ability to 
solubilize large amounts of gases. A subset of perfluorocarbon particles, perfluorocarbon 
nanodroplets (PFCnDs), are becoming increasingly investigated because their versatile 
characteristics make them attractive diagnostic and therapeutic agents. PFCnDs are the 
sub-micrometer, liquid version of microbubbles (MBs) which are commonly used as 
ultrasound contrast agents in clinic. PFCnDs are superior to MBs in terms of increased 
circulation lifetimes and the ability to extravasate hyperpermeable vasculature. 
Additionally, PFCnDs can be phase-changed into MBs through user-controlled energy 
input, thereby simultaneously possessing the advantages associated with their nanoparticle 
size and the associated contrast enhancement of MBs. Given these characteristics, the work 
presented herein concentrated on developing “next generation” PFCnDs exhibiting 
enhanced diagnostic and image-guided therapeutic characteristics.  
Acoustic activation has been the most well studied of the mechanisms to phase-
change PFCnDs. However, laser-initiated activation has several advantages compared to 
acoustically-triggered PFCnDs. Laser-triggered PFCnDs are safe, the activation event is 
well-controlled, and they are more comprehensive imaging agents since they act as 
multimodal contrast agents, supplementing ultrasound contrast with photoacoustic (PA) 
contrast.  
In the first two aims, innovative image-processing and engineering techniques that 
improve laser-activated PFCnDs’s diagnostic abilities in cancer applications are described. 
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In Chapter 3, I describe the development of laser-activated PFCnDs which exhibit 
increased imaging depth, photoabsorber stability and overall biocompatibility. In 
conjunction, I developed an image-processing algorithm capable of creating background-
free images from the unique temporal contrast provided by PFCnDs (explained in detail in 
Appendix A). Chapter 4 describes a platform consisting of multicolored PFCnDs capable 
of selectively initiating ultrasound/photoacoustic contrast from unique PFCnD 
subpopulations. To highlight the platform’s usefulness, different lymphatic transport 
mechanisms were studied in a murine tumor-draining lymph node model. In addition to 
elucidating different trafficking mechanisms, the multicolored PFCnDs helped uncover 
important in vivo PFCnD characteristics not identified by previous acoustic-or laser-
activated PFCnDs research. Future work will include targeting multicolored PFCnDs to 
various cancer receptors for improved diagnosis. 
The third aim studies the ability of laser-activated PFCnDs to improve stem cell 
angiogenic therapy. Stem cell angiogenic therapies have struggled to achieve their clinical 
potential due to high amounts of cell death shortly after implantation. Given that the 
implantation site is severely ischemic, I hypothesized that oxygen-loaded PFCnDs could 
help mitigate the harsh conditions of the oxygen-deprived tissue and result in increased cell 
survival for more efficacious therapies. Additionally, I sought to bring more control over 
oxygen levels by studying whether laser-activation of PFCnDs induced increased release 
of oxygen. Findings demonstrated that laser-activated PFCnDs can influence oxygen levels 
in image-guided and passive mechanisms, impacting cell viability and hypoxic pathway 
regulation. Future work will focus on studying PFCnD impact in in vivo models, and 
engineering PFCnDs that exhibit enhanced control over activated oxygen release.  
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The last chapter highlights the accomplished PFCnD advances, and describes future 





Two of the leading causes of death, cancer and ischemic cardiovascular disease 
(CVD), have continued to affect millions of Americans over the past several decades. 
Despite the large amount of labor and resources devoted to combating these diseases, 
diagnosis is difficult and treatments often ineffective. Nanoparticles (NPs) have been 
touted as the key to revolutionizing medical diagnoses and therapy, thereby improving 
patient outcomes. However, in clinic, NPs have struggled to fulfill their potential, 
particularly in the diagnostic area. The goal of the following work was to develop NPs that 
show clinical potential as diagnostic agents and as image-guided therapeutics.  
Specifically, I sought to improve perfluorocarbon nanodroplet (PFCnD) technology 
so that they can become more clinically relevant diagnostic and image-guided therapeutic 
agents. PFCnDs are the sub-micrometer, liquid version of the ubiquitously used ultrasound 
contrast agent, perfluorocarbon microbubbles (MBs). Recently, PFCnDs have gained 
interest due to their ability to expand upon favorable MB characteristics of enhanced 
ultrasound contrast and therapeutic delivery. Compared to MBs, PFCnDs have longer 
circulation lifetimes and can access tissue spaces that larger MBs cannot. In addition, 
PFCnDs can be phase-changed into MBs, via an external trigger, allowing for enhanced 
image contrast, and on-demand therapeutic release. 
Of the various PFCnD subtypes, laser-activated PFCnDs present unique advantages, 
such as a well-controlled phase-change behavior and multimodal (photoacoustic and 
ultrasound) imaging contrast. Thus, the following work focused on advancing laser-
activated PFCnDs technology to determine their clinical utility. Specifically, the presented 
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work demonstrates PFCnD developments that allow for background-free imaging, 
increased image penetration depth, the ability to simultaneously provide multiple signals 
via one imaging modality (i.e. multiplexed imaging), and image-guided therapeutic release. 
To accomplish these achievements, the following specific aims were established and 
met:  
 Aim 1: Engineer clinically relevant, translatable PFCnDs 
Light-triggered PFCnDs rely on a photoabsorber to initiate the phase-change. 
Therefore, the chosen photoabsorber is of critical importance in regards to attaining clinical 
relevance and future translation. I investigated the use of copper sulfide (CuS) 
nanoparticles as photoabsorbers, and studied their ability to produce efficient laser-
activated PFCnDs. The constructed CuS-PFCnDs were examined in tissue models and 
compared to traditionally used photoabsorber-PFCnD constructs. CuS-PFCnDs’s ability to 
provide in vivo image contrast was studied in an inflammatory murine model. In 
conjunction, background-free image processing was developed that can be used with other 
laser-activated PFCnDs for enhanced image quality.  
  Aim 2: Design a multicolored PFCnDs platform for multiplexed ultrasound 
and photoacoustic imaging 
Multiplexing, i.e. the ability to send multiple signals over a shared medium, is a 
valuable tool for increasing efficiency and breadth of relayed information. In relation to 
medical imaging, optical imaging modalities have most thoroughly exploited this 
phenomenon given the vast array of available probes, e.g. fluorophores. In recent years, 
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the capability of clinically relevant imaging modalities to multiplex has become 
increasingly studied in order to improve diagnosis efficacy, particularly for heterogeneous 
diseases, such as cancer. In this aim, I engineer a multiplexed imaging platform based on 
laser-activated PFCnDs and ultrasound/photoacoustic imaging. The system’s multiplexed 
sensitivity is shown in tissue mimicking phantoms, and then used to study different PFCnD 
lymphatic trafficking mechanisms in a tumor draining lymph node murine model. 
Interesting in vivo characteristics are uncovered that help establish PFCnDs’s role as future 
diagnostic and therapeutic agents.  
 Aim 3: Investigate PFCnDs in improving current ischemic cardiovascular 
therapies. 
Current stem cell angiogenic treatments suffer from high amounts of implanted cell 
death, rendering them ineffective. The high amount of cell death, is partly attributed to the 
extreme hypoxia, i.e. low oxygen, of the implanted site. The ability of oxygenated, laser-
activated PFCnDs to ameliorate hypoxia-related cell effects is shown. Additionally, I 
demonstrated that PFCnDs provide image-guided oxygen release in a localized manner, 
and cause biomaterial changes that can enhance in vivo vascularization.  
 
The accomplished work is significant because it builds upon foundational laser-
activated PFCnD research and elevates their clinical utility as diagnostics and image-
guided therapeutics. Looking forward, as photoacoustic imaging becomes more 
commonplace in the clinic, the advancements established in the subsequently described 
thesis work will become increasingly utilized.   
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 Perfluorocarbon nanodroplets (PFCnDs) 
Perfluorocarbon particles (PFCps) have a long standing history in medical 
applications.1-2 A subset of these particles, PFCnDs, have become increasingly studied as 
diagnostic and therapeutic agents because of the versatility associated with their 
controllable phase-change characteristic.3-8  PFCnDs are the sub-micrometer, liquid 
version of the clinically used ultrasound contrast agent, PFC MBs. They are composed of 
a stabilizing shell and perfluorocarbon core. Compared to MBs, PFCnDs offer several 
advantages including increased circulation lifetimes and the ability to extravasate 
hyperpermeable vasculature for directly diagnosing and treating diseased tissue.9 
Furthermore, PFCnDs can be phase-changed into MBs, most commonly via acoustic or 
laser irradiation, thus retaining the ability to act as enhanced ultrasound contrast agents. In 
addition to their favorable diagnostic properties, PFCnDs can be loaded with therapeutic 
drugs or gases and deliver their cargo in an image-guided manner. 
2.1.1 Acoustically-activated PFCnDs in relation to laser-activated PFCnDs 
Of the PFCnD subtypes, acoustically activated PFCnDs have been around the 
longest and as a result, are the most thoroughly studied. Almost two decades ago, Apfel et 
al. designed PFC droplets and demonstrated the particles could be converted into 
microbubbles with ultrasound irradiation, a technique called acoustic droplet vaporization 
(ADV).10 Since then, parameters influencing ADV such as particle size, composition, and 
ultrasound parameters have been studied by various groups.5-6, 11-13 ADV occurs when 
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PFCnDs are irradiated with ultrasound at a sufficient peak negative pressure to cause a 
phase-change of their perfluorocarbon liquid core.13 Traditionally, this has been 
accomplished using perfluorocarbon cores with boiling points lower than physiological 
temperatures. As ADV can also occur with PFCnD of high boiling point cores, alternative 
mechanisms of vaporization, such as nucleation based ADV, have recently been 
suggested.9  
Despite laser-activated PFCnDs only being developed in 2012,4 their close 
relationship to acoustically activated PFCnDs has allowed for their rapid progression as 
diagnostic and therapeutic agents. The essential difference between acoustic- and laser-
activated PFCnDs is that the latter require an encapsulated photoabsorber and laser 
irradiation to initiate the phase-change.4 This discrepancy  allows for certain advantages 
over acoustically activated PFCnDs, including a highly-controlled vaporization event, and 
the ability to supplement ultrasound enhancement with photoacoustic imaging. Given these 
benefits, the purpose of the following work is to expand upon laser-activated PFCnDs’s 
desirable properties and increase their clinical utility as diagnostic and image-guided 
therapeutic agents.  
In order to gain a thorough appreciation of laser-activated PFCnDs’s multimodal 
imaging capabilities, it is important to understand the fundamentals of ultrasound and 
photoacoustic imaging, and their relation to laser-activated PFCnD image contrast.  
2.1.2 Ultrasound imaging 
Ultrasound imaging is one of the most widely used imaging modalities. It is 
routinely used in a range of applications because of its low-cost, portability, and ability to 
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safely provide anatomical information at sub-millimeter spatial resolutions.14-16  
Ultrasound imaging works by using a transducer to irradiate a tissue with high-frequency 
( > 20 kHz) sound waves. The tissue’s inherent properties cause a portion of the sound 
waves to be reflected back to the transducer, which will collect the information, amplify 
the signal electronically, and create a gray-scale image. Reflections, waves that carry the 
same frequency as the original waves emitted by the transducer, occur when the sound 
waves pass from one tissue type to another with different acoustic impedances.  
Acoustic impedance (Z) is defined as:  
𝑍 = 𝜌 ∗ 𝑐 
where ρ is the density of the tissue and c is the speed of sound within the tissue. The portion 
of the sound wave reflected back, versus the remaining portion that is either scattered or 
continues traveling through the interrogated tissue, is proportional to the difference in 
acoustic impedance between the two materials. Tissues with a larger acoustic impedance 
mismatch will reflect a larger percentage of the sound wave, appearing brighter on gray-
scale images. For this reason, gas microbubbles are routinely used as ultrasound contrast 
agents because of the large impedance difference between endogenous tissue and the gas-
filled microbubbles.14 Additionally, gas microbubbles can exhibit oscillations in size that 
allow for nonlinear harmonic imaging, further facilitating differentiation from the 




2.1.2.1 Laser-activated PFCnDs as ultrasound contrast agents 
In their nanodroplet form, PFCnDs provide minimal ultrasound contrast as there is 
an insignificant acoustic mismatch between PFCnDs’s liquid core and the surrounding 
tissue or bodily fluids. However, upon phase-change, PFCnDs expand five times their size 
into gaseous microbubbles, acting as enhanced ultrasound contrast agents.4 Hence, 
PFCnDs can persist in nanodroplet form until they are externally triggered to provide 
ultrasound contrast. Dependent on the perfluorocarbon core, PFCnDs can exist as a stable 
or transient microbubble, thus affecting their ultrasound contrast (See Section 2.2.1 Types 
of PFCnDs and their different image contrast for a detailed explanation.). 
2.1.3 Photoacoustic imaging 
Photoacoustic imaging is based off a phenomenon discovered by Alexander Graham 
Bell when he observed that a solid material exposed to pulsed light would produce a sound 
wave.17 For decades this knowledge sat untouched, but with the advancement of laser 
technology the photoacoustic phenomena saw a revival in widespread applications.18 In 
medical imaging, photoacoustic imaging proved useful in supplementing ultrasound 
anatomical information with functional and molecular data.19  
 Medical photoacoustic imaging involves interrogating a tissue of interest with 
tuned, nanosecond pulsed laser light. Photoabsorbers that absorb the irradiated light’s 
specific wavelength will undergo a thermoelastic expansion that produces a pressure 
wave.18, 20 A transducer detects the produced pressure waves, i.e. acoustic waves, and based 
on the time they are received, determines the source of wave production and constructs an 
image.21  
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The initial pressure wave (po) is described as:  
𝑝𝑜 =  𝜇𝑜 ∙ 𝐹 ∙ Γ 
where μo is the optical absorption coefficient of the photoabsorber, F is the light fluence, 
and Γ is the Grüneisen parameter, a variable accounting for volume expansion, specific 
heat, and the speed of sound.22 The produced photoacoustic signal is a highly dependent 
on the material’s absorption characteristics, and the light energy that reaches the material. 
For this reason,  near-infrared (NIR)23 or extended NIR spectral range 24, 600-1200 nm, 
light sources are typically used. The reduced scattering and endogenous absorption within 
this regime allows for increased penetration in what is referred to as the optical imaging 
window (Figure 1). 
 
Figure 1. In vivo imaging within the optical windows allows for increased image 




2.1.3.1 Endogenous and exogenous photoabsorbers 
Photoabsorbers can be either endogenous or exogenous absorbers. Endogenous 
photoabsorbers are those that are found intrinsically in tissue and include deoxygenated 
and oxygenated hemoglobin, fat, and melanin.25 As such, photoacoustic imaging can 
provide functionally relevant data without the introduction of contrast agents by tuning the 
irradiated light to the corresponding endogenous photoabsorber’s absorption spectrum.26-
27 However, introduction of exogenous photoabsorbers allows for enhanced image contrast, 
increased penetration depth and ultimately more advanced diagnostic imaging.28 
Exogenous photoabsorbers most commonly include dyes or inorganic nanoparticles.25, 28 
The size and ease of functionalization of NPs facilitates molecularly specific imaging, 
greatly augmenting the in vivo diagnostic potential of photoacoustic imaging.29-30 
Additionally, NPs can be synthesized to absorb at distinct wavelengths to reduce effects of 
endogenous absorbers.22 
Photoacoustic imaging’s reliance on optical excitation grant it certain advantages, 
such as the ability to image various probes at once.22, 31 Due to the broad absorption 
spectrum of most photoabsorbers, this is typically done by assessing acoustic responses to 
different wavelength excitations, and then applying spectral unmixing techniques to 
resolve the different photoabsorbers.32 The advancement of photoabsorbers with narrow 
absorption spectra can allow for real-time imaging of multiple photoabsorbers, i.e. 
multiplexed photoacoustic imaging.33 One limitation of relying on optical excitation is that 
photoacoustic imaging is limited to an imaging depth of 5 centimeters or less; however, 
this is still about a ten-fold increase compared to other optical based imaging modalities.22 
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2.1.3.2 Laser-activated PFCnDs as photoacoustic contrast agents 
Laser-activated PFCnDs consist of a perfluorocarbon core, surfactant shell and an 
encapsulated photoabsorber. Upon pulsed laser irradiation, tuned appropriately to the 
incorporated photoabsorber, the photoabsorber will absorb the light energy and undergo its 
typical thermoelastic expansion. The thermoelastic expansion from the many encapsulated 
photoabsorbers produces a slight increase in temperature, but more significantly, pressure 
aberrations which act as nucleation sites, causing the perfluorocarbon core to vaporize and 
transition into a microbubble. The vaporization event gives off an intense photoacoustic 
signal, several times greater than the photoacoustic signal provided by the encapsulated 
photoabsorber.4, 34 Therefore, laser-activated PFCnDs exhibit both a vaporization-
associated photoacoustic signal, and a photoabsorber-associated photoacoustic signal. 
Depending on the perfluorocarbon core utilized, the vaporization-associated photoacoustic 
signal can be a one-time or repeatable event (See Section 2.2.1 Types of PFCnDs and their 
different image contrast for detailed explanation). 
2.1.4 USPA imaging  
Due to the natural synergy between ultrasound and photoacoustic imaging, 
researchers merged them and began exploiting their multimodal capabilities.35-36 
Ultrasound/photoacoustic (USPA) imaging combines ultrasound’s anatomical information 
with photoacoustic imaging’s functional information. Together, the two can provide 
comprehensive view of the interrogated tissue. Comparing USPA imaging to routinely 
used clinical imaging modalities, such as magnetic resonance imaging (MRI), computer 
tomography (CT), positron emission tomography (PET), and single-photon emission 
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computed tomography (SPECT), USPA imaging is safer (non-ionizing radiation), cost-
effective and portable.37-38 The biggest limitation of USPA imaging is its reduced imaging 
penetration compared to modalities that use ionizing radiation. However, USPA can 
penetrate deeper than any other optical-based modalities to date (Figure 2). With the 
continual advancement of contrast agents, USPA imaging can become a reliable presence 
in clinical settings. 
 





 PFCnDs as diagnostic imaging agents 
PFCnDs’s close relationship to the widely used diagnostic agent, MBs, made for a 
natural transition into studying PFCnDs as diagnostic agents.6, 39 Their small size, increased 
lifetimes, and ability to extravasate, expand their diagnostic potential relative to MBs.8 
PFCnDs can interact with extravascular lesions, and when functionalized, give molecularly 
relevant data. For cancer purposes, the ability to provide non-invasive, in situ information 
is greatly advantageous over current techniques. Biopsies, the clinical standard, are prone 
to sampling error, often misinforming physicians on the extent of disease heterogeneity.40 
Additionally, metastatic lesions, if present, are often of a different cellular makeup than 
primary tumors, making them difficult to detect and treat.40 MRI and CT, combined with 
nuclear medicine (PET or SPEC), offer whole body imaging making them useful for 
diagnostic and staging purposes; however, these modalities are costly and use ionizing 
radiation, limiting their repetitive use.41 As PFCnDs provide USPA contrast, using them 
for molecular imaging could help diagnose and frequently monitor therapy efficacy without 
burdens of safety or cost. 
Most commonly, PFCnDs have been studied as diagnostic agents in cancer and 
cardiovascular disease applications.5, 9, 42 To date, the majority of in vivo systemic injection 
studies have focused on cardiovascular applications,43 likely a result of the challenges 
associated with getting sufficient PFCnD extravasation needed for solid tumor diagnosis.44-
45 Progress in smaller, targeted PFCnD will open more opportunities for extravascular 
applications. Already, PFCnDs have shown the ability to traffic to sentinel lymph nodes 
and provide image contrast when injected subcutaneously or intradermally, indicating their 
potential in metastatic applications.46-47 
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2.2.1 Types of PFCnDs and their different image contrast 
Depending on the perfluorocarbon core, PFCnDs will provide different types of 
USPA contrast. PFCnDs, even those synthesized with perfluorocarbons with boiling points 
lower than physiological temperatures, i.e. perfluoropentane (B.P. 27ºC), can persist as 
nanodroplets in vivo. This is explained by an increased Laplacian pressure (ΔP), defined 
as:  




and a function of surface tension (σ) and droplet radius (r). The elevated pressure inside 
the droplet effectively increases the boiling point, allowing low boiling PFCnDs to exist as 
metastable droplets. The differences in image contrast arise once PFCnDs are triggered 
with an energy input. Upon induced phase-change, low boiling PFCnDs will rapidly 
expand and become a stable microbubble.39 PFCnDs synthesized with higher boiling point 
perfluorocarbons, i.e. perfluorohexane (B.P 57ºC), can also phase-change, but will only 
exist as a transient microbubble, rapidly recondensing back into the liquid state. This subset 
of PFCnDs “blink” and provide a sharp vaporization-associated photoacoustic and 
ultrasound signal each time a phase-change takes place, i.e. with each pulse of laser 
irradiation.47-48 Choosing the type of PFCnD will depend on the intended purpose as well 
as the available imaging set-up. One-time PFCnDs will work with most imaging set-ups as 
they do not require high-frame rate capture, but they are less stable and overtime may 
spontaneously vaporize in vivo. Blinking PFCnDs have increased stability in vivo, but 
require high-frame rate USPA to capture the rapid phase-change and recondensation event.   
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 PFCnDs as image-guided therapeutic agents 
PFCnDs’s favorable diagnostic characteristics make them equally desirable 
therapeutics. As such, PFCnDs have been investigated as therapeutic agents beginning in 
the 2000s.49 The goal is that by allowing for localized release of therapeutics, via an 
external stimulus, PFCnDs can minimize the drug’s undesirable side effects while 
increasing therapy efficacy.50 Loading is often limited to PFCnD shell space as the 
perfluorocarbon core is both extremely hydrophobic and lipophobic.1, 51 Loading of 
hydrophobic therapeutic agents is accomplished by loading within the hydrophobic portion 
of the shell, between the hydrophilic exterior and perfluorocarbon core.52-53 Hydrophilic 
therapeutics can also be incorporated into PFC particles using double emulsion techniques, 
but result in micron size particles.54-55 Interestingly, perfluorocarbons are extremely 
effective at solubilizing gases because of their weak van der Waals interactions, a 
characteristic imparted by PFC’s C-F bond.56  Depending on the PFC used, PFCnDs can 
solubilize oxygen at about 40-50% (v/v).56 Hence, PFCs have been studied to deliver 
various therapeutics, including drugs, genes and gases.3  
2.3.1 Therapeutic delivery  
2.3.1.1 Drug-loaded PFCnDs 
There are several mechanisms in which PFCnDs can deliver drugs to cellular 
targets. The most widely studied method involves conversion of PFCnDs into MBs, 
followed by inducing inertial or stable cavitation to increase cellular membrane 
permeability (reviewed in Rapoport, 2012).8 This mechanism of therapeutic delivery uses 
extracellular PFCnDs. Alternatively, targeted and untargeted PFCnDs can be taken up by 
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cells and be phase-changed intracellularly.57 However, there has not been much research 
regarding drug delivery using this method. Thus far, a study observing cell death after 
acoustically induced intracellular PFCnD phase-change, i.e. not drug-induced, is one of the 
few studies conducted observing cellular effects following PFCnD activation.58 An 
additional manner of PFCnD drug delivery is through fusion of the lipid PFCnD shell with 
a cell bilayer.59 This is typically done by incorporating a lipid disrupting membrane, e.g., 
melatinin, that causes PFCnD fusion into a cell’s lipid bilayer, thereby bypassing 
endosomes and releasing cargo directly into the cytosol. 59-61 
2.3.1.2 Gas-loaded PFCnDs 
Compared to bulkier therapeutics, delivery of gases is more straightforward given 
their small size. PFCs can solubilize such large amounts of gases that they have been used 
as liquid ventilators.56 Oxygen, the gas of interest for the following work, is loosely 
dissolved within PFCs. This is in contrast to how it is strongly bound to haemoglobin.56 
Thus, PFC-dissolved O2 is readily released to tissues in need. This is beneficial in some 
cases, but poses challenges in controlling oxygen release, as the oxygen will rapidly diffuse 
out of PFCps based on the concentration gradient. However, certain measures can be taken 
to prevent excessive oxygen diffusion, such as altering the PFCnD shell.62-63 Thus, PFCnDs 
can deliver gas passively, based on oxygen gradients, or actively, with the application of 
an external stimuli that will compromise shell permeability.64-65  
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 Research Goals 
The potential of laser-activated PFCnDs as diagnostics and therapeutics is evident; 
however, in order for them to successfully progress to their claimed clinical utility, more 
studies focused on clinically relevant advancements are needed. The goal of the following 
work was to bridge this gap and showcase laser-activated PFCnDs’s clinical potential. To 
accomplish this, I developed PFCnD technology that allows for background-free imaging, 
increased image penetration depth, the ability to simultaneously provide multiple signals 
via one imaging modality (i.e. multiplexed imaging), and image-guided therapeutic release 






NPs can be readily classified into two groups: organic (i.e. liposomes, micelles, 
polymeric complexes, etc.) or inorganic (i.e. metallic, semiconductor, silica, etc.). Each 
group has its inherent strengths and weaknesses. Organic NPs are great therapeutic carriers, 
biodegradable and effectively cleared, but are typically incapable of providing image 
contrast on their own. Thus, they are poor diagnostic imaging agents. On the other hand, 
the majority of inorganic NPs are superior contrast agents, but struggle as efficacious 
therapeutics. Additionally, most inorganic NPs have limited biodegradability and 
clearance, which raises concerns over their clinical potential due to questionable long-term 
toxicity and bioeffects.66 In the quest for ideal diagnostic and therapeutic NPs, researchers 
have turned to combinations of NPs.67-68 Unfortunately, while combining NPs may 
augment the strengths of individual particles, they are often unable to overcome inherent 
barriers. For instance, combinations of particles may result in increased contrast, but at the 
expense of biocompatibility or limited clearance. 
Laser-activated PFCnDs present a unique construct with which to synergistically 
combine organic (micelle) and inorganic components (copper sulfide (CuS) nanoparticles) 
and produce NPs with enhanced image contrast that retain high clinical translation 
potential. Thus, I developed CuS-PFCnDs that merge the increased photoacoustic and 
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ultrasound contrast enhancement of PFCnDs with the favorable biocharacteristics of CuS 
NPs.  
Laser-activated PFCnDs have been synthesized with various photoabsorbers 
ranging from organic dyes to inorganic nanoparticles.4, 69-72 The motivation for studying 
CuS NPs as the photoabsorber was based on considering characteristics of the ideal 
photoabsorber. The ideal photoabsorber would absorb at long wavelengths for increased 
penetration resulting in a higher signal-to-noise ratio, have good photothermal stability and 
efficiency, and be biodegradable with good clearance properties. Thus far, photoabsorbers 
used as PFCnD triggers have struggled to fulfill these requirements. For instance, gold 
nanorods (AuNRs) can be synthesized to absorb within desirable wavelength range, 
including 1064 nm; however, they are neither biodegradable nor effectively cleared, 
provoking concerns over long-term cytotoxicity and safety.72 Also, upon pulsed laser 
irradiation, anisotropic gold nanoparticles are prone to melting and morphing shape, 
altering their spectrum and thus limiting long-term applications.73  Finally, many dyes have 
been utilized as triggers, but the majority absorb in the NIR or at shorter wavelengths, 
resulting in reduced penetration depths. In addition, dyes are susceptible to photobleaching, 
once again limiting long-term applications.70-71  
Copper sulfide (CuS) NPs are inorganic, semi-conductor nanoparticles primarily 
used as photothermal agents due to their photothermal stability.74-75 CuS NPs are non-
cytotoxic, biodegradable, and are cleared within a reasonable time frame.76 They absorb 
within the second optical imaging window (1000 nm to 1350 nm), ideal for achieving 
clinically relevant penetration depths with increased signal-to-noise ratio.24 One drawback 
of CuS NPs is their lower extinction coefficient and photothermal efficiency compared to 
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gold nanoparticles; thereby, requiring significant CuS NP concentrations for enhanced 
photoacoustic contrast.77 Fortunately, this limitation is trivial when using CuS NPs in laser-
activated PFCnDs. A modest amount of CuS NPs is enough to initiate PFCnD vaporization. 
The resulting phase-change gives an intense photoacoustic signal and a gaseous PFC 
microbubble (MB) which provides enhanced ultrasound contrast. Hence, combining CuS 
NPs with PFCnDs synergistically overcomes limitations associated with CuS NPs and the 
aforementioned laser-activated PFCnD challenges.   
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 Methods and Materials 
3.2.1 Synthesis of CuS NPs  
Copper sulfide nanoparticles (CuS NPs) were synthesized according to previously 
described methods.74 Hydrodynamic size of CuS NPs, measured using a Zetasizer Nano 
ZS (Malvern), was shown to be ~11 nm, which agreed with TEM images. Citrate-coated 
CuS NPs were PEGylated via addition of thiolated poly(ethylene glycol) (mPEG-SH, 5 
KDa Layson Bio) (1 mgml-1). The solution was left to react overnight under gentle stirring. 
The following day the solution was washed of excess PEG using 30 kDa Amicon centrifuge 
filters and resuspended in DI H2O at an O.D. of ~10.  
3.2.2 Comparison of CuS NPs and 1064 nm AuNRs  
Stability of synthesized CuS NPs was compared against 1064 nm absorbing 
AuNRs. Solutions containing either CuS NPs or AuNR of equal O.D.’s were irradiated at 
various energies (1064 nm, 10-Hz pulse repetition rate) for 600 pulses (60 s). Afterwards, 
UV-Vis measurements were taken to study any changes in absorbance spectrum due to 
alteration in particle shape (i.e. stability).  
3.2.3 Fluorination of CuS NPs 
To fluorinate CuS NPs, 3.5 ml of CuS NPs at OD ~10 were added to 20 ml of 
ethanol and 300 µl of 1H, 1H, 2H,2H-Perfluorodecanethiol (Sigma). The solution was 
stirred and left to react overnight.  After 24 hours, fluorinated CuS NPs were washed in a 
50 kDa Amicon centrifuge filters at 1000 rcf for 10 minutes. The remaining solution, <1 
ml, was placed under reduced pressure (Buchi Rotavapor) to remove any remaining ethanol 
 21 
or excess perfluorodecanethiol and leave a film of fluorinated CuS NPs. One ml of PBS 
was added to the dried CuS NPs and sonicated to resuspend the CuS NPs.  Spectrums of 
PEGylated CuS NPs and fluorinated CuS NPs were taken on an Evolution 220 UV-Vis 
Spectrophotometer (Thermo Fisher). Zeta potential measurements to ensure successful 
coatings were taken with a Zetasizer Nano ZS.  
3.2.4 Synthesis of CuS-PFCnDs 
Synthesis of CuS-PFCnDs was modified from previously developed methods.4, 72, 
78 Briefly, 50 µl of perfluoropentane (FluoroMed L.P.) and 150 µl of 1% v/v Zonyl FSO 
fluorosurfactant (Sigma) were added to the resuspended CuS NPs. The solution was 
vortexed for 10 seconds and sonicated in an ice-cold ultrasonic water bath (VWR, 180 W) 
for 5 minutes or until the solution became milky with minimal excess perfluoropentane 
solution. CuS-PFCnDs were centrifuged at 100 rcf for one minute to remove any excess 
CuS NPs that aggregated and remained in solution. The supernatant was taken and further 
washed at 1000 rcf for 5 minutes to get rid of any excess CuS NPs in solution. 
Hydrodynamic size of CuS-PFCnDs was characterized with a Zetasizer Nano ZS after the 
washing steps.  
3.2.5 USPA Image acquisition 
All imaging experiments were conducted using a 40-MHz ultrasound and 
photoacoustic imaging probe (LZ-550, Visualsonics Inc.) coupled to a combined 
ultrasound and photoacoustic imaging system (Vevo LAZR, Visualsonics Inc). The laser 
was operated at 1064 nm wavelength producing 5-7 ns laser pulses at 20-Hz pulse 
repetition rate. The fluence was measured to be between 6-9 mJcm-2.  
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3.2.6 Phantom preparation  
A poly(acrylamide) tissue mimicking phantom with a pipette inclusion was 
constructed as previously described by our group.70 Briefly, 40% acrylamide solution was 
mixed with water, ammonium persulfate and tetramethylethylenediamine. The mixture 
was poured into a mold and allowed to solidify around a pipette fixed in place to create a 
void for future pipette insertion.   
3.2.7 Phantom imaging 
CuS-PFCnDs were diluted (2.0% v/v) in PBS. The solution was pipetted out and 
the pipette with solution was placed within the void of the phantom (Figure 2). The imaging 
probe, placed above the phantom, was acoustically coupled to the phantom using 
ultrasound gel. The probe was positioned such that the optical focus occurred at the center 
of the pipette’s cross section. Ultrasound B-mode and photoacoustic (1064 nm) images 
were collected simultaneously for 100 frames at a rate of 5 fps.  
3.2.8 Comparison of CuS- and AuNR-PFCnDs activation at different depths 
To demonstrate the advantages of CuS-PFCnDs, the generated PA amplitude of 
CuS-PFCnDs to AuNR-PFCnDs were compared at different imaging depths. The 
synthesized AuNRs had a peak absorbance at 800 nm. To prepare the different PFCnDs, 
CuS NPs and AuNR solutions of the same O.D. (10) were fluorinated. Next, PFP and a 
stabilizing shell (bovine serum albumin in PBS) were added and the mixture was sonicated 
until PFCnDs formed. To ensure a fair comparison, CuS-PFCnDs and AuNR-PFCnD sizes 
were characterized with a Zetasizer Nano ZS and found to both be within 5% of each other. 
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Additionally, a plate reader was used to ensure roughly equal concentrations of the two 
types of PFCnDs, based on absorbance.  
To compare the vaporization ability at increasing depths of CuS-PFCnDs and 
AuNR-PFCnDs, a flow phantom was designed where different levels of milk could be 
added. The milk levels were used to mimic tissue absorbance properties, with higher levels 
of milk corresponding to deeper imaging depths. To detect vaporization, a 20 MHz 
transducer (Visualsonics MS250) was placed at a fixed distance below the sample. A 
gelatin layer (8% wt/vol) containing graphite particles was placed on top of the transducer 
in order to protect it from direct laser irradiation that could produce image/signal artifacts. 
Above the graphite-gelatin layer was a pure gelatin layer (8% wt/vol) with thin-wall 
silicone tubes running horizontally and perpendicular to the imaging plane of the 
ultrasound transducer.  
During laser irradiation, the imaging samples, containing either CuS-PFCnDs or 
AuNR-PFCnDs, were stationary or flowing through the tubes at 2 mlmin-1. The flow rate 
was controlled by a syringe pump (Fusion 400, Chemyx Inc.). The flow phantom ensured 
that unvaporized PFCnDs entered the imaging plane at each photoacoustic frame, thereby 
allowing vaporization-associated photoacoustic signal comparison between CuS-PFCnDs 
and AuNR-PFCnDs. A Vibrant laser (Opotek) operating at the particle’s peak absorption, 
either 800 nm for AuNR-PFCnDs or 1064 nm for CuS-PFCnDs, was used to irradiate the 
sample from above. The laser produced 5-7 ns laser pulses at a 10-Hz repetition rate. 
Fluences for each wavelength were chosen based on the allowed American National 
Standards Institute (ANSI) limits, i.e., 32 mJcm-2 for 800 nm and ~100 mJcm-2 for 1064 
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nm.79 Milk was added in increments of 0.25 cm until a final height of 3.0 cm of milk 
between the laser air-beam and the sample was reached. At each milk height, photoacoustic 
signal was captured under no flow and under flow conditions. The photoacoustic signal 
during the no flow condition was averaged and subtracted from the average photoacoustic 
signal during flow to calculate the vaporization-associated photoacoustic signal. This value 
was then normalized to the smallest milk height (0.25 cm) for the respective groups. In 
some cases, when there was no vaporization occurring, fluctuations in the photoacoustic 
signal resulted in slightly negative PA% values.  
3.2.9 In vivo imaging 
Studies conducted adhered to approved protocols by the Institutional Animal Care 
and Use Committee at Georgia Institute of Technology. Mice (nu/nu) were anesthetized 
using a combination of isoflurane (1.5-2.5%) and O2 (0.8 Lmin
-1). For all in vivo studies, 
150 µl of as-prepared CuS-PFCnDs were injected intravenously through the jugular vein. 
3.2.9.1 Spleen imaging 
CuS-PFCnDs were first tested in a murine spleen to verify they could provide 
significant photoacoustic and ultrasound contrast. After particle injection, 30 minutes was 
allotted to allow for circulation and uptake of CuS-PFCnDs by the reticuloendothelial 





3.2.9.2 Dermatitis murine model: Lymph node imaging 
A murine exhibiting spontaneous dermatitis was used to study CuS-PFCnDs in a 
more applicable in vivo model. The inguinal lymph node was localized using ultrasound 
and Doppler imaging. Ultrasound images of the lymph node were taken after CuS-PFCnD 
injection but before CuS-PFCnD laser activation to ensure no spontaneous vaporization of 
the CuS-PFCnDs. Two minutes after injection, the lymph node was irradiated at 1064 nm 
and USPA images were collected for one minute. Following the irradiation, ultrasound 
images were taken at distinct time points to monitor the change in CuS-PFCnD-enhanced 
ultrasound contrast over time. 
3.2.10 Background-free imaging algorithm  
The unique temporal photoacoustic and ultrasound signal of laser-activated CuS- 
PFCnDs was exploited through image processing. Following laser induced vaporization, 
pixels containing phase-changed PFCnDs exhibit a decay in photoacoustic signal, and an 
increase in ultrasound signal. Using a developed algorithm that identifies pixels which 
exhibit the characteristic photoacoustic and/or ultrasound trend, and discards endogenous 
signal and/or noise, results in a clear map of PFCnD locations. Overlaying the produced 
PFCnD localized image over an ultrasound image, for anatomical reference, results in an 
easy visualization of CuS-PFCnDs. Although initially developed for CuS-PFCnDs, the 
image processing can be applied to other laser-activated PFCnDs. Please refer to Appendix 
A for a more detailed explanation of the algorithm, and examples regarding photoacoustic- 
and ultrasound-based background-free image production. 
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 Results  
3.3.1 Synthesis and fluorination of CuS NPs 
CuS NP absorbance depends on d-d transition;77 therefore, fluorination of CuS NPs 
did not significantly alter their characteristic UV-Vis spectrum, ability to absorb at 1064 
nm or their structure (Figure 3a, b). However, differences in surface charge were observed 
after fluorination (Figure 3c). Following successful surface coating, CuS NPs became 
soluble in perfluorocarbon solutions for future inclusion in nanodroplets (Figure 3d).   
3.3.2 Synthesis of CuS-PFCnDs 
 Upon sonication, an emulsion of PFCnDs with incorporated CuS NPs was formed. 
There were unencapsulated CuS NPs that were washed away during the centrifugation 
steps. However, the remaining PFCnDs had a blue hue, indicative of CuS NP presence. 
The CuS-PFCnDs were monodisperse (polydispersity index <0.15) with a mean 
hydrodynamic size of 250 nm (Figure 3e). Given that Zonyl FSO has a highly hydrophilic 
head, the zeta potential of synthesized CuS-PFCnDs is relatively neutral, -7.04 +/-1.01 mV. 
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Figure 3. (a) Fluorination of CuS NPs did not significantly alter their spectrum or (b) their 
size and structure, shown by TEM images. (c) Successful coating was confirmed by 
measuring particle zeta potential at each step. (d) After fluorination, CuS NPs were soluble 
within PFC solution (lower layer) while PEGylated CuS NPs remained in PBS. (e) 
Hydrodynamic size was measured using dynamic light scattering shortly after sample 







3.3.3 Comparison of CuS NPs to AuNRs following pulsed irradiation 
CuS NPs have increased photothermally stability compared to AuNRs, an 
important characteristic for PFCnD applications requiring repeated vaporization events. 
CuS NPs are more thermodynamically stable than AuNRs because of their spherical 
shape.80 Therefore, despite repetitive pulsed-laser irradiation at high fluences, their UV-
vis spectrum remains unchanged. This is in contrast to 1064 nm absorbing AuNRs’ 
spectrum, which begins to shift left as nanorods are converted into spherical particles 
(Figure 4).
 
Figure 4. Solutions of AuNRs and CuS NPs of equivalent optical densities were irradiated 
(number of pulses = 600) at different energies. (a)  Laser irradiation affected AuNR 
stability, which led to altered spectrum and reduced ability to absorb at 1064 nm. (b) CuS 
NP spectrum was not affected by laser irradiation, even at the highest energies, confirming 
CuS NP photothermal stability. 
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3.3.4 Tissue-mimicking phantom studies 
3.3.4.1 CuS-PFCnDs photoacoustic and ultrasound response 
Synthesized CuS-PFCnDs provided dramatic photoacoustic and ultrasound 
enhancement. Prior to laser irradiation, ultrasound imaging of the sample revealed no 
ultrasound contrast, confirming their stability.  Fluences of 6-9 mJcm-2 proved enough to 
activate the CuS-PFCnDs and cause their characteristic photoacoustic signal decay and 
ultrasound enhancement (Figure 5). With laser-activated PFCnDs, it is easy to distinguish 
the PFCnD vaporization photoacoustic signal from the photoabsorber signal due to the 
former’s significantly higher intensity. Upon irradiation, the majority of PFCnDs are 
vaporized, resulting in a strong, immediate photoacoustic signal (Figure 5b, top panel - PA 
column).  Subsequent laser pulses produce a reduced photoacoustic signal mainly 
attributed to CuS NPs and a small portion of leftover CuS-PFCnDs (Figure 5b, middle and 
lower panels - PA column). The result is an exponential decay in photoacoustic signal over 
time (Figure 5c). As expected, the ultrasound contrast exhibits the inverse effect, rapidly 
increasing as the nanodroplets are converted into stable microbubbles (Figure 5b, US 
column). After a few laser pulses, the area becomes saturated with microbubbles and the 
ultrasound contrast plateaus at a maximum (Figure 5d).  
 30 
 
Figure 5. (a) Schematic of phantom and imaging setup. The 2-D imaging plane is indicated 
by the dashed square. The laser irradiation is applied from the top of the phantom. (b) 
Photoacoustic and ultrasound imaging frames show the difference in contrast at various 
time-points throughout laser irradiation; pulse repetition frequency of 20 Hz.  (c) Typical 
of PFCnD vaporization, photoacoustic signal rapidly decays while (d) ultrasound contrast 







3.3.4.2 Comparison of CuS-PFCnDs to traditional laser-activated PFCnD 
Different levels of milk were used to mimic optical properties of tissue and assess 
how penetration depth affected PFCnD activation ability (Figure 6a). At the lowest level 
of milk, photoacoustic signal was increased during flow conditions for both samples, 
indicative of successful PFCnD vaporization (Figure 6b). However, AuNRs-PFCnDs could 
no longer be activated at 1.75 cm of milk; whereas, CuS-PFCnDs retained 40% of their 
vaporization capability at a depth of 3 cm (Figure 6c).  
 
Figure 6. (a) Schematic of the flow-phantom design used for capturing photoacoustic 
signals at different depths of milk. (b) The photoacoustic signal during no flow, indicated 
by the pink regions, is largely attributed to the photoabsorber within the PFCnDs. During 
flow (green), the photoacoustic signal increases as a result of the intense vaporization 
event. (c) The change in PA% was calculated by subtracting the photoacoustic signal under 
no flow from the vaporization signal during flow, and then normalized to the smallest milk 
height. CuS-PFCnDs outperform Au-PFCnDs in vaporization abilities as imaging 





3.3.5 In vivo imaging  
3.3.5.1  CuS-PFCnD characterization in a murine spleen 
CuS-PFCnDs provide distinct ultrasound and photoacoustic signal in vivo. Due to 
their size and biocharacteristics CuS-PFCnDs primarily accumulate in the red pulp tissue 
of the spleen.81-82 This was confirmed by significant photoacoustic/ultrasound signal after 
irradiation at 1064 nm. Both the photoacoustic and ultrasound signals were processed with 
the developed algorithm (see Appendix A for detailed description) and background-free 
images were formed indicating PFCnD accumulation and activation throughout the spleen 
(Figure 7). 
 
Figure 7. CuS-PFCnDs primarily accumulate in the spleens. Thirty minutes after injection 
the spleen was imaged and USPA data collected. (a) Background-free ultrasound images 
are obtained using the developed image processing algorithm clearly localizing CuS-
PFCnDs within the spleen. (b) By applying a similar processing algorithm to the collected 
photoacoustic data we are also able to produce a background-free photoacoustic image. 





3.3.5.2 Lymph node imaging in a murine dermatitis model 
Given the advantages of CuS-PFCnDs, they were tested in a model of higher 
clinical relevance, specifically a spontaneous dermatitis murine model. Prior to injection, 
the enlarged inguinal lymph node was located using grayscale and color Doppler 
ultrasound imaging (Figure 8). After systemic injection, the particles were allowed to 
circulate for a few minutes, and then 1064 nm pulsed laser irradiation was started resulting 
in an increase of photoacoustic and ultrasound signals (Figure 9a, middle panel). After the 
initial laser pulse, there was the characteristic increased in photoacoustic signal which 
decayed over time as more laser pulses were applied. Coupled with photoacoustic signal 
decrease, there was a rapid increase in ultrasound signal from the lymph node. The changes 
in both photoacoustic and ultrasound signal are similar to what was seen in tissue models 
and in the spleen, suggesting that a portion of CuS-PFCnDs remained within the 2-D 
imaging plane, becoming entrapped either within vessels or in lymph node tissue. Given 
that the vasculature of an inflamed lymph node becomes hyperpermeable, it is possible 
some CuS-PFCnDs were able to extravasate. This hypothesis is supported by the 
ultrasound enhancement seen throughout the entire volume of the lymph node and 







Figure 8. 3-D Doppler image demonstrating the enlarged 
inguinal lymph node and dilated vasculature. 
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Figure 9. (a) Photoacoustic and ultrasound images of the lymph node before injection 
(top), after injection and upon starting laser irradiation (middle), and at the end of 
irradiation (bottom) show successful vaporization of CuS-PFCnDs and increased 
photoacoustic and ultrasound contrast throughout the lymph node. The yellow star denotes 
a bubble used as a marker for ensuring the same 2D imaging plane was maintained before 
and after injection.  (b) Changes in photoacoustic and ultrasound contrast prior to CuS-
PFCnD injection and then after injection at the start and end of the laser irradiation period. 
The photoacoustic and ultrasound contrast seen after irradiation are similar to observations 




Figure 10. Ultrasound signal after period of lasing (red regions indicate when the laser is 
on). Ultrasound signal persists for several minutes and gradually falls as PFC diffuses out 
of PFCnDs or created MBs are washed out of plane.  
The background-free image algorithm was applied to better understand CuS-
PFCnD distribution within the lymph node. Interestingly, the photoacoustic analysis was 
unable to localize vaporized CuS-PFCnDs as clearly as in the spleen. This is likely due to 
the lower CuS-PFCnD concentration in the lymph node and the fact that a portion of the 
flowing CuS-PFCnDs are activated by scattered laser light outside of the ultrasound 
imaging plane. The combination of these factors results in a reduced amount of CuS-
PFCnDs photoacoustic response within the imaging plane. Fortunately, as CuS-PFCnDs 
simultaneously provide sustained, enhanced ultrasound contrast, they could clearly be 
identified by applying the ultrasound-based image processing. CuS-PFCnDs were 
localized throughout the lymph node and surrounding vasculature (Figure 11a). Areas 
containing activated CuS-PFCnDs show an increase in ultrasound signal of up to 70%, 




Figure 11. Ultrasound-based image processing, based on the pixel’s positive slope (yellow 
versus blue ROIs), selectively identifies CuS-PFCnDs throughout the lymph node. Scale 
















 Discussion  
Use of CuS NPs as photoabsorbers imparts several benefits for PFCnDs. CuS NPs 
exhibit photoacoustic contrast as deep as five centimeters due to their extended NIR 
absorbance.83 This signifies that CuS-PFCnDs can be activated at increased depths over 
other laser-activated PFCnDs, which was verified with the comparison to 800nm AuNR-
PFCnDs. Considering that depth penetration is one of the biggest limitations in USPA 
imaging, this presents a significant advancement.  
Another benefit of CuS NPs as the photoabsorber, is that they have shown 
biodegradability in vivo, overcoming concerns of long-term toxicity and biocompatibility 
that other inorganic particles face. One study directly compared long-term bioeffects of 
CuS NPs and Au NPs and showed that one month after systemic injection 90% of CuS NPs 
were excreted versus only 4% of Au NPs.76 Alternatively, CuS NPs can be synthesized at 
sizes that pass through the renal system for rapid clearance, and still possess absorbance in 
the extended NIR.84-85 
The ability of systemically injected CuS-PFCnDs to dramatically enhance USPA 
contrast presents several opportunities. In regards to clinical applications, CuS-PFCnDs 
were able to provide contrast throughout the entirety of an inflamed lymph node. 
Ultrasound images show that phase-changed CuS-PFCnDs accumulate in the lymph node 
and persist for several minutes afterwards. The sustained contrast suggests that a portion 
of the produced MBs get stuck in small capillaries or in the lymph tissue, a result of 
PFCnDs extravasating the inflamed vasculature. Morphological changes experienced 
during inflammatory diseases, such as lymphangiogenesis and vasculature remodeling, 
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closely resemble changes seen in pre-metastatic lymph nodes.86-90 Therefore, CuS-PFCnDs 
may be used to uncover diseased lymph nodes based on the extent of CuS-PFCnD signal 
seen throughout the vasculature. This method provides different information, relevant to 
vasculature changes, from the traditional subcutaneous injections used to study lymphatic 
transport. Additionally, intravenous injections overcome certain limitations associated with 
subcutaneous injection of larger particles (> 100 nm), where the majority remain entrapped 
at the injection site, struggling to directly enter the lymphatics and consequently, the lymph 
node.91-93 Although, the ability of particles to enter the lymph node from the vasculature 
needs to be further examined, CuS-PFCnDs could still be able to highlight the vasculature 
changes associated with certain diseases. However, it is important to consider the model 
being utilized, as pre-metastatic vascular remodeling can vary.90  
CuS-PFCnDs also have potential applications in areas outside of the lymph node. 
Their natural tendency to accumulate in the red pulp tissue of the spleen, where they are 
eventually endocytosed by resident red pulp macrophages (RPMs), could help elucidate 
RPM’s response in vivo. Recently, RPMs have shown the ability to present antigens to T-





For several decades, diagnostic agents have been judged on their ability to 
differentiate diseased versus healthy tissue. As knowledge regarding tissue heterogeneity 
and its implications increased, 95-97 so too has the demand for in vivo diagnostic platforms 
capable of conveying more detailed information. Multiplexed imaging, the ability to 
simultaneously visualize functional parameters and/or molecular targets using one imaging 
modality, is well-suited to accomplish this task. To date optical based modalities have 
offered the most robust multiplexing abilities due to the availability of diverse imaging 
probes.98 However, the limited depth penetration of optical modalities greatly restricts their 
clinical utility.98-99 Hence, great attention has been placed on increasing the multiplexing 
abilities of clinical relevant imaging modalities. Thus far, nuclear medicine has shown that 
it can effectively differentiate various phenotypes by selective targeting with various 
radiometals.98, 100 However, the acquisition time associated with multiplexed positron 
emission tomography (PET) or single-photon emission computed tomography (SPECT) 
can be lengthy, i.e., several minutes. Additionally, since PET or SPECT are typically 
combined with MRI or CT imaging,98 there are concerns of high-costs and/or safety 
regarding repetitive imaging feasibility.41 To address these limitations, I have engineered 
a platform for multiplexed ultrasound and photoacoustic (USPA) imaging based on laser-
activated perfluorocarbon nanodroplets (PFCnD). 
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The innovative platform consists of multicolored, laser-activated PFCnDs and USPA 
imaging to noninvasively provide multiplexed and even, multimodal contrast. The platform 
relies on encapsulating unique photoabsorbers into distinct PFCnD subpopulations, where-
upon user-specified laser irradiation can selectively activate PFCnD subgroups to induce 
USPA contrast. After successfully showing the platform’s feasibility, I demonstrate its 
potential in a mouse model of a tumor-draining lymph node. The multiplexed imaging 
capabilities of multicolored PFCnDs helped elucidate distinct lymphatic trafficking 
mechanisms, i.e. intravascular versus intradermal, in a single imaging session. 
Additionally, multicolored PFCnDs’s helped uncover in vivo PFCnD characteristics that 
significantly expand their potential uses. Future iterations of the presented platform will 
focus on targeting PFCnD subpopulations towards different receptors to provide 
comprehensive anatomical and molecular information of diseased tissue. 
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 Materials and Methods 
4.2.1 Synthesis of multicolored PFCnDs 
UV-Vis spectrophotometry (Evolution 220; Thermo Scientific) confirmed the 
selected hydrophobic dyes (Epolight 9151, Epolight 3832; Epolin, Inc.) had absorption 
spectra with minimal overlap. Perfluoropentane (FluoroMed, L.P.) was used for the PFCnD 
core and a mixture of phospholipids was used for the stabilizing shell. To synthesize the 
colored PFCnDs, 20 µl of 1,2- distearoyl-sn-glycero-3-phosphocholine (DSPC, 10 mg/mL; 
NanoCS Inc.) and 15 µl of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (DSPE-PEG(2000), 25 mg/ml; Avanti Polar Lipids, 
Inc.) lipids in chloroform, were added to a 50 ml pear shaped flask. Dye solutions were 
prepared in chloroform (1 mg/ml), and 100 µl of the desired dye was added to the lipid 
solution. Finally, 2 ml of chloroform were added to the flask to facilitate the production of 
a smooth lipid cake. The flask was placed under reduced pressure (Rotavapor; BÜCHI 
Labortechnik) to remove the chloroform, and the result was a thin, colored lipid cake. One 
ml of PBS was added to the flask and sonicated (VWR, 180 W) to resuspend the lipids and 
dye and create micelle structures. The solution was transferred to an 8 ml scintillation vial 
and 75 µl of perfluoropentane were added. The vial was vortexed and sonicated in ice-cold 
water (VWR, 180 W) until the solution became milky and there was no remaining 
perfluoropentane bolus visible. The resulting PFCnDs were washed to remove excess dye 
by placing the solution in a 1.5 ml microcentrifuge tube and centrifuging them at 100 rcf 
for one minute. The supernatant was pulled off, leaving any aggregated dye behind. The 
same synthesis process was repeated with the other dye, and the two synthesized droplet 
sets were kept separately for characterization. 
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In studies requiring fluorescently labeled particles, PFCnDs were synthesized 
according to the same protocol, but an additional 1.6 µl of fluorescent dye (DiI, 3mg/ml; 
Thermofisher) was added to the lipid-dye-chloroform mixture. Being highly lipophilic, DiI 
integrates itself within the lipid shell. Synthesized DiI-PFCnDs were tested after synthesis 
to ensure PFCnD vaporization was not affected.  
4.2.2 Characterization of multicolored PFCnDs 
A dynamic light scattering instrument (Zetasizer Nano ZS; Malvern Instruments 
Ltd.) was used to characterize the PFCnDs. For size measurements, 1 ml of a 1:100 stock 
dilution of PFCnDs in PBS was placed in a plastic cuvette.  To study surface charge, 500 
µl of a 1:100 PFCnD stock solution in nanopure water (Barnstead Smart2Pure, Thermo 
Scientific) was placed in a folded capillary zeta cell. 
4.2.3 USPA image acquisition  
All imaging experiments were conducted using a 40-MHz ultrasound and 
photoacoustic imaging probe (LZ-550; FUJIFILM VisualSonics Inc.) coupled to a 
combined ultrasound and photoacoustic (USPA) imaging system (Vevo LAZR; 
VisualSonics Inc). The tunable Nd:YAG laser operated at either a 680 nm or 1064 nm 
wavelength producing 5-7 ns laser pulses at a 20-Hz pulse repetition rate. The fluences 
were measured to be between 12-15 mJ·cm-2 at 680 nm and 6-9 mJ·cm-2 at 1064 nm, well 




4.2.4 Phantom studies 
4.2.4.1 Assessing selective photoacoustic/ultrasound signal of multicolored PFCnDs 
A flow phantom was used to demonstrate that each PFCnD subset provides 
selective photoacoustic and ultrasound contrast at their respective absorption wavelengths. 
Considering the PFCnD vaporization is a dynamic event, a dynamic phantom, i.e. flow, 
helps to easily differentiate between vaporized and unvaporized PFCnDs. To construct the 
phantom, the face of a clear plastic box was drilled with three equally spaced holes. This 
process was repeated on the opposite face of the box, and optically and ultrasonically inert 
silicone tubing (HelixMark; Freudenberg Medical, ID 0.250” OD 0.374”) was threaded 
from one side to the other. The spacing of the tubes ensured all three samples could be 
irradiated and imaged at the same time, for fair comparison. Solutions (1:100 stock 
dilution) of 1064 nm-PFCnDs, 680 nm-PFCnDs, and blank PFCnDs (i.e., no dye) were 
prepared and loaded into separate 10 milliliter syringes. An 18-guage needle and an 
accompanying 10 milliliter sample-filled syringe were attached to one side of the tubing, 
enabling flow through the phantom box. A syringe pump (Fusion 400; Chemyx Inc.) 
controlled the flow rate of samples through the tubes at either 0 ml·min-1 (i.e. stationary) 
or at 2 ml·min-1, a velocity which ensured continuously unvaporized sample for each laser 
pulse. The phantom box was filled with degassed water and the imaging probe was placed 
perpendicular to the tubes such that the optical focus of the integrated laser fibers was 
aligned with the cross-sectional area of the tubes. Photoacoustic and ultrasound data were 
collected for approximately 30 seconds at 680 nm and 1064 nm laser irradiation. 
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4.2.4.2 Mixture of PFCnDs  
Different ratios of 1:100 dilutions of 680 nm-PFCnDs to 1064 nm-PFCnDs (1:3, 
2:2, and 3:1) were mixed together and placed in three separate 10 mL syringes. Samples 
were monitored to ensure settling of PFCnDs did not occur during the imaging process. 
Using the flow phantom previously described, the samples were irradiated at 680 nm or at 
1064 nm while flowing through the tubes at 2 ml·min-1 or stationary. For both wavelengths, 
a region of interest within the center of each tube was selected, and the vaporization-
associated photoacoustic signal from each wavelength was determined (n = 10 
photoacoustic frames). A period (n = 10 photoacoustic frames) from the stationary baseline 
photoacoustic signal (i.e., photoabsorber-associated photoacoustic signal) was averaged 
and subtracted from the averaged vaporization-associated photoacoustic signal. The result 
allowed for comparison of vaporization-associated photoacoustic signal of each excitation 
wavelengths across the differing ratios. 
4.2.5 In vivo imaging 
The subsequently described small animal studies adhered to protocols approved by 
the Institutional Animal Care and Use Committee at the Georgia Institute of Technology. 
Mice (nu/nu) were anesthetized with a combination of isoflurane (2.5%) and O2 (1.0 L·min
-
1) and placed on an animal heating pad, regulated at 37°C, during imaging. After acquiring 
ultrasound and photoacoustic data, the algorithm described in Appendix A was performed 
to produce background-free images. 
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4.2.6 Spleen imaging 
To ensure in vivo efficacy of the multicolored PFCnDs, a nu/nu mouse model was 
utilized. A 1:1 cocktail from stock solutions of the two PFCnD subpopulations was 
prepared and 150 µl were intravenously injected via the jugular vein. The particles were 
allowed to circulate for 30 minutes, and then the spleen was imaged at 680 nm and again 
at 1064 nm. After imaging sessions, mice were either kept for observation or euthanized 
via CO2 asphyxiation followed by cervical dislocation. 
4.2.7 In vivo breast cancer model 
4T1 murine breast cancer cells were cultured in Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (Invitrogen) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Nu/nu mice were injected with 50 µls of 4T1 cells (1x107 
cells/mL) into the mammary fat pad. Tumor sizes were monitored for several days, and 
ultrasound imaging was conducted to observe any changes in the draining inguinal lymph 
node. To study different lymphatic trafficking capabilities of PFCnD, intradermal and 
intravascular injections were conducted as follows. At 5-6 days after inoculation, 100 µl of 
1064 nm-PFCnDs were injected intradermally at the tumor site, while mice were under the 
aforementioned anesthesia. The particles were slowly injected to prevent drastic pressure 
changes at the injection site for reducing the risk of premature droplet vaporization or 
altering particle drainage. At the respective time points (24 or 72 hours), mice were 
anesthetized again, and the inguinal lymph node was located with ultrasound imaging. A 
second injection of 100 µl of 680 nm-PFCnDs were injected intravenously through the 
jugular vein. After 1 minute, USPA images of lymph nodes were obtained by first 
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irradiating at 1064 nm and then at 680 nm. After imaging was complete, the animals were 
sacrificed via a sodium pentobarbital based veterinary euthanasia drug (150 mg/kg IP) and 
cervical dislocation. Lymph nodes were resected and fixed for histology. 
4.2.8 Intradermally injected PFCnDs trafficking mechanisms 
4.2.8.1 USPA and IVIS imaging  
After realizing that intradermal PFCnDs successfully trafficked to lymph nodes, 
additional studied were conducted to better understand how they are transported. Healthy 
mice (n = 9) were injected with 100 µl of only 680 nm-PFCnDs in the breast tissue area. 
At 1.5 (n = 2), 24 (n =4) and 72 (n =3) hours after injection, USPA imaging was conducted 
and the intensity of photoacoustic signal within the lymph node analysed. The baseline (i.e. 
endogenous plus photoabsorber signal) was subtracted from the peak photoacoustic signal 
(i.e. vaporization-associated photoacoustic signal) to compare the difference in 
vaporization-associated photoacoustic intensity at the different time points. In addition to 
USPA, IVIS imaging was performed at 24 hours post injection of fluorescently labelled 
PFCnDs to monitor their spatial distribution (n =2).  
4.2.9 Functionalization of PFCnDs 
To demonstrate the feasibility of multicolored PFCnDs for use as eventual 
molecular diagnostic tools, the efficacy of functionalized PFCnDs was studied. A protocol 
for directional conjugation of antibodies to gold nanoparticles101 was adapted for PFCnDs 
(please refer to Appendix B) to produce HER2 targeted PFCnDs.  
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4.2.10 Functionalized PFCnDs binding assay 
SKBR3 cells, a HER2 expressing breast cancer cell line, was used for studying 
HER2 targeted PFCnDs. Cells were cultured in 2-chamber well chamber slides 
(ThermoFisher). After cells had reached 50-70% confluence, they were stained with 
CellTracker Green dye (ThermoFisher). Then, 15 µl of either HER2 functionalized or 
PEGylated PFCnDs (both DiI labelled) were incubated with the cells (1.5 ml media per 
well). After two hours, cells were washed with PBS several times. Cells were then fixed 
with 10% formalin for 10 minutes, washed with PBS and coverslips mounted. A Zeiss 




 Results  
4.3.1 Synthesis of Multicolored PFCnDs 
Multicolored PFCnD were synthesized by encapsulating two photoabsorbing dyes 
with minimally overlapping absorption spectra within distinct lipid-shelled PFCnD 
subpopulations (Figure 12b). Both PFCnD subsets, which will subsequently be referred to 
as 680 nm-PFCnDs and 1064 nm-PFCnDs given the wavelength at which they phase-
change, were characterized using dynamic light scattering. For multiplexing purposes, it is 
essential that the PFCnD subpopulations have nearly identical characteristics, excluding 
the encapsulated photoabsorber, to ensure a fair comparison regarding image contrast, 
pharmacokinetics and stability for downstream in vivo experiments. Accordingly, 
characterization studies indicated that the subpopulations had a similar hydrodynamic size, 
350 nm, and zeta potential, -34.7mV +/- 1.6 (Figure 12b). 
 
Figure 12. (a) UV-Vis of selected dyes showed minimal overlap. (b) The subpopulations 
had very similar size distributions. Insert shows synthesized multicolored PFCnDs.  
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4.3.2 Selective activation in tissue-mimicking phantom studies 
PFCnD subpopulations selectively responded to tuned pulsed-laser irradiation 
wavelengths (i.e. 680 nm and 1064 nm). The flow phantom ensured that unactivated 
PFCnDs could enter the imaging plane at each photoacoustic frame for comprehensively 
studying the spatiotemporal USPA contrast of the disparate PFCnDs groups (Figure 13a).  
At 680 nm laser irradiation, the 680 nm-PFCnD sample vaporized, resulting in the 
expected intense photoacoustic signal. There was no observable photoacoustic signal from 
either the blank or 1064 nm-PFCnDs. During flow conditions, the photoacoustic signal of 
vaporized PFCnDs is increased, but relatively stable, because unactivated PFCnDs are 
constantly flowing through the laser irradiation plane and being immediately vaporized. 
Thus, giving off a steady level of vaporization associated photoacoustic signal (Figure 
13b,d). Ultrasound signal, on the other hand, is not enhanced because the phase-changed 
PFCnDs will not exhibit ultrasound enhancement until the produced microbubble reaches 
a certain size and stability. This occurs out of the imaging plane due to the flow rate 
utilized.  When the flow is stopped, i.e. from 12 to 22 seconds, there are no unactivated 
PFCnDs to vaporize and thus no new phase-change events occur, resulting in a rapid 
decrease in 680 nm photoacoustic signal down to a baseline. Ultrasound signal, in contrast, 
rapidly increases under stationary conditions, because the vaporized PFCnDs have time to 
accumulate as microbubbles in the imaging plane (Figure 13c,f). Upon irradiation at 1064 
nm, an analogous trend in USPA signal was observed for the 1064 nm-PFCnDs sample 
(Figure 13e,g). 
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 Due to the high energy at 680 nm and slight absorbance of the 1064 nm dye at this 
wavelength, there was a slight ultrasound enhancement from 1064 nm-PFCnDs (Figure 
13f). However, the ultrasound crosstalk was minimal and not accompanied by any 
observable photoacoustic signal increase. Nonetheless, for later lymph node studies, 




Figure 13. (a) Designed flow phantom that allowed for simultaneous imaging of different 
PFCnD subpopulations. (b) Photoacoustic signal at either 680 nm or 1064 nm only elicits 
signal from the appropriate PFCnD subpopulation (flow is 2 ml·min-1). (c) Ultrasound 
signal, during 0 ml·min-1 flow, shows accumulation of produced MBs. (d-g) Photoacoustic 
signal and ultrasound signal during the 30 seconds of laser irradiation. Flow starts at 0 
seconds and is stopped from 12 to 22 seconds, indicated on graph d by the green (flow on) 
and red (flow off) regions. During this time photoacoustic signal drops and ultrasound 




4.3.3 Quantitative photoacoustic imaging  
PFCnDs can convey information regarding quantities of subpopulations by 
comparing relative photoacoustic signals. Different mixtures of varying 680 nm-PFCnDs 
to1064 nm-PFCnD ratios exhibited photoacoustic intensity from each wavelength (680 and 
1064 nm) that corresponded to the relative proportion of phase-changed PFCnDs (Figure 
14). At increasing ratios of 680 nm-PFCnD to 1064 nm-PFCnD, the photoacoustic signal 
at 680 nm laser irradiation increased, while the photoacoustic signal at 1064 nm decreased 
(Figure 14b). Analogously, higher relative concentrations of 1064 nm-PFCnD 
corresponded to increased 1064 nm photoacoustic signal and decreased 680 nm signal.  
 
Figure 14. (a) Different mixtures of 680 nm-PFCnDs to 1064 nm-PFCnDs were imaged 
in a flow phantom. (b) Photoacoustic signal at either 680 nm or 1064 nm was correlated to 
the amount of PFCnD subpopulation present. (c) Images of the first photoacoustic frame 
show how the signal changes as PFCnD subpopulations concentrations are changed (red: 
680 nm photoacoustic signal, green: 1064 photoacoustic signal).  
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4.3.4 Image-processing techniques with multicolored PFCnDs 
The dual contrast of laser-activated PFCnDs allows versatile image processing 
techniques that enhances the robustness of the platform. Please refer to Appendix A for a 
detailed explanation on background-free image construction.  
Laser-activated PFCnDs have unique spatiotemporal photoacoustic and ultrasound 
signals; therefore, either, or both, data set can be processed to form background-free 
images. Often, either photoacoustic or ultrasound signal is superior due to factors such as 
PFCnD location, concentration and endogenous contrast. To demonstrate this phenomenon 
in relation to multicolored PFCnDs, a mouse spleen was studied and the USPA contrast 
following 680 and 1064 nm light irradiation examined. Following pulsed 680 nm laser 
irradiation, the 680 nm-PFCnD group exhibited USPA contrast. Since the PFCnDs have a 
fixed location, their photoacoustic signal is at a maximum following the first laser pulse, 
i.e. vaporization-associated signal, and then rapidly decreases to a baseline. However, there 
was a lot of endogenous photoacoustic contrast as well (Figure 15a). Ultrasound signal 
exhibited the inverse effect; rapidly increasing over time as more microbubbles were 
formed. Processing the ultrasound data led to a background-free image of the 680 nm-
PFCnDs, that is much cleaner than the original photoacoustic image (Figure 15b).  
Next, irradiation at 1064 nm activated the 1064 nm-PFCnD group. Due to the high 
baseline ultrasound signal from the previously produced microbubbles, PFCnD phase-
change based on ultrasound signal alone was not possible; however, the PFCnD 
vaporization-associated photoacoustic signal remains largely unaffected and after using the 
developed algorithm to distinguish it from endogenous signal/noise, a similar background-
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free image is produced (Figure 15d). Thus, multiple sets of colored PFCnDs can be readily 
distinguished from one another based on user-controlled inputs and processed with the 
best-suited modality.  
 
Figure 15. (a) Photoacoustic imaging of the spleen at 680 nm overlaid on an ultrasound 
image. (b) Upon processing the ultrasound data, a background-free image is produced that 
more clearly conveys the location of vaporized PFCnDs. (c) Photoacoustic imaging of the 
spleen at 1064 nm overlaid on an ultrasound image. (d) Photoacoustic-based image 
processing of the 1064 nm irradiated sample reduces endogenous signal and noise. Scale 









4.3.5 Lymph node imaging with multicolored PFCnDs 
To highlight a more clinically relevant application, distinct lymph node trafficking 
mechanisms were studied using multicolored PFCnDs. For both the 24-hour and 72-hour 
time-points, both PFCnD subpopulations were successfully activated after irradiation at 
their corresponding wavelengths; however, they were distinctly localized in the lymph 
node (Figure 16). The intravenously injected PFCnDs (680 nm-PFCnDs), introduced 
moments before imaging, were located throughout the majority of the lymph node, given 
its extensive vascular bed.102  Photoacoustic-based background free-imaging was 
performed to localize the 680 nm-PFCnDs (Figure 16-middle column), although they also 
exhibited ultrasound contrast. Interestingly, the intradermal injected PFCnDs (1064 nm-
PFCnDs), injected either 24 or 72 hours before imaging, only exhibited photoacoustic 
signal and were confined to one area of the lymph node, specifically on the side proximal 
to their injection site (Figure 16, first column). For the 24-hour time-point, there was also 






Figure 16. Photoacoustic-based processed images showing the different locations of 
intradermal versus intravenously injected PFCnDs. Red arrow indicates a lymph vessel. 
The 24 or 72-hour time point refers to the intradermally injected PFCnDs. In both cases, 









4.3.6 Lymphatic trafficking of intradermal injected PFCnDs 
After observing intradermal PFCnD signal much longer than anticipated (days after 
injections), additional studies were executed to help elucidate their trafficking mechanisms. 
At 1.5 hours after intradermal injection, USPA imaging showed no accumulation of 
PFCnDs in the lymph node. However, at 24 and 72 hours, there was the distinct 
photoacoustic signal arising from vaporization, indicating PFCnD accumulation occurs 
over these time points.  The observed lymph node photoacoustic signal was higher at 24 
hours compared to 72 hours (Figure 17a). IVIS imaging at 24 hours confirmed PFCnD 
presence in the lymph node, but also demonstrated a lot of PFCnDs remain at the injection 
site (Figure 17b). 
 
Figure 17. (a) Photoacoustic signal of the lymph node at various time points after 
intradermal PFCnD injection. (b) IVIS image after 24 hours showing the PFCnDs 





4.3.7 PFCnD Functionalization  
Successful molecular imaging with targeted PFCnDs was demonstrated. Confocal 
images showed that HER2 functionalized PFCnDs successfully targeted the HER2 
expressing SKBR3 cell line. The control, PEGylated PFCnDs did not attach to SKBR3 
cells (Figure 18). These preliminary results show the potential of molecular imaging with 
functionalized PFCnDs. 
 
Figure 18.  HER2 functionalized PFCnDs target SKBR2 cells more effectively.                      






Multicolored PFCnDs bring the diagnostic advantages associated with multiplexed 
imaging to a clinically relevant imaging modality. Distinct subgroups selectively provide 
USPA contrast based on laser irradiation wavelength, and the photoacoustic signal is a 
directly correlated to the concentrations of different subpopulations. Thus far, the 
platform’s utility was demonstrated with two PFCnD subpopulations, but as the 
development of photoabsorbers with narrow absorption spectra continues, more 
subpopulations can be added. The advantages of using laser-activated PFCnDs for 
multiplexed imaging over simple photoacoustic probes are that PFCnDs also provide 
ultrasound contrast, the ability to deliver increased therapeutic cargos in an image-guided 
fashion, and their unique contrast allows them to be easily distinguished from endogenous 
signal to form background-free images. 
The developed multicolor PFCnD platform presents an effective method for 
studying particle dynamics, as experiments can be performed in a single model and 
imaging session. This allows for a higher throughput, more uniform comparison, and 
facilitates discoveries. Up until now, many PFCnD studies have focused on synthesis and 
improving imaging performance, with the majority of these studies conducted in tissue 
phantoms, in vitro or in preliminary in vivo models.48, 57, 78, 103 Additionally, most of the in 
vivo studies focused on short-term applications, on the order of minutes to few hours.53, 64-
65 Given the reported potential of PFCnDs, it is necessary to more thoroughly explore their 
in vivo capabilities. Therefore, multicolored PFCnDs were employed in vivo to study 
murine tumor-draining lymph nodes (TDLNs) and elucidate PFCnD trafficking 
mechanisms. 
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As expected, intravenously and intradermally injected PFCnDs reached the TDLN 
via different mechanisms. Both provide sufficient photoacoustic contrast, at the tested 
time-points, but only the intravascular exhibits a change in ultrasound contrast. By using 
the multicolored PFCnD platform, the discrepancies in PFCnD characteristics related to 
different biological interactions is easily discernable. It was surprising that intradermally 
injected PFCnDs could remain stable and provide their characteristic photoacoustic signal 
for up to 72 hours, significantly longer than time frames of previous studies, i.e. typically 
a few hours. The fact that intradermal PFCnDs no longer provide ultrasound contrast 
remains to be further studied. However, based on their increased presence in nanodroplet 
form and the fact they provide photoacoustic but not ultrasound contrast suggests that 
PFCnDs were taken up by cells.  
Further confirming this hypothesis is the location of intradermally injected PFCnDs 
compared to intravenously injected PFCnDs, while the latter group is present throughout 
the lymph node, the former is only located in one region of the lymph node. Based on the 
time scale in which intradermal PFCnDs traffic to the lymph node (Figure 17) and their 
location within the lymph node, it is likely they are trafficked to TDLNs via cellular-
mediated transport.104-105 Antigen presenting cells (APCs), specifically dendritic cells, have 
been shown to transport various nanoparticles via afferent lymphatic vessels with similar 
time-frames to what PFCnDs’s exhibit.91, 105-106 Dendritic cell uptake would also explain 
why there is no ultrasound contrast. Dendritic cells preferentially uptake smaller particles, 
and a smaller PFCnD that is vaporized would not provide enhanced ultrasound contrast in 
MB form.107 108 Alternatively and/or complimentarily, PFC could diffuse out of PFCnDs 
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during the 24-72 hour time frame, further reducing the particles size and ability to provide 
discernable ultrasound contrast. This hypothesis will be confirmed by histology studies. 
If confirmed, the fact that intradermally injected PFCnDs traffic to the lymph node 
via APCs presents advantageous therapeutic opportunities. TDLNs are an important site 
for immune system regulation, and thus in disease treatment.109-111 Additionally, dendritic 
cells are known to have an instrumental role in inducing the adaptive immune system.112-
114  Multicolored PFCnDs could increase therapy delivery by facilitating endosomal escape 
via the vaporization event. They could also facilitate combination therapies. Different 
therapeutics could be encapsulated within distinct PFCnD subpopulations, and delivered 
in a sequential, image-guided manner.  
Altogether, multicolored PFCnDs will allow for important in vivo diagnostic, 
monitoring and treatment capabilities. Molecular targeting of PFCnDs was successfully 
shown in vitro. Next steps will involve functionalizing multicolored PFCnDs 
subpopulations toward various cancer receptors to gain a better understanding of tumor 
heterogeneity. Compared to the current clinical standard, biopsies followed by pathology, 
multicolored PFCnDs will increase patient comfort while reducing sampling error, 





Peripheral arterial disease (PAD) is an ischemic cardiovascular disease that affects 
around 20% of the elderly population.115-116 Patients with PAD have a reduced quality of 
life and increased occurrence of severe cardiac complications.117-119 If left untreated, PAD 
can develop into critical limb ischemia, a condition with grimmer prognosis.116 For patients 
that have progressed to this stage the most common treatment is surgical intervention; 
however, due to the inherent risk of the procedures, about 30% of patients are unsuitable 
for invasive surgery and will face limb amputation or possible death.120  Thus, it is 
imperative to develop treatments that are beneficial to even the most refractory patient. 
One such option is stem cell angiogenic therapy. Stem cells can differentiate into relevant 
cell types and possess tissue healing paracrine and immunomodulatory effects.121-122 
However, while stem cell angiogenic therapy has shown promise in in vitro and pre-clinical 
models, its progress has been hindered by inefficacy in the clinical setting.123-124 Until stem 
cell angiogenic therapy can demonstrate real clinical improvements, it will remain an 
unrealistic therapeutic option and leave many patients without an appropriate remedy. 
There are several reasons for stem cell angiogenic therapy inefficacy.125-127 One 
major reason, and the focus of this work, is the high amount of stem cell death following 
implantation.125, 128-129 Given the diseased state of the implantation site, it is unsurprising 
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that the conditions faced by injected stem cells are incredibly hostile. The ischemic tissue 
is severely hypoxic, nutrient deprived, and has high levels of reactive oxygen species and 
inflammatory cytokines; factors culminating in the implanted cells quickly undergoing 
apoptosis.127-131 It is hypothesized that increasing stem cell survival will result in improved 
clinical outcomes. As such, researchers have studied various methods to increase cell 
survival, ranging from pre-conditioning cells to improving the implantation technique 
and/or stem cell delivery vehicle.132-135  
The following work focuses on mitigating the severely hypoxic conditions through 
a controlled oxygen delivery platform. Appropriate oxygen level is essential to stem cell 
survival as well as functionality.136-138 Levels of oxygen must be high enough to prevent 
cell apoptosis, but low enough to initiate important angiogenic signaling pathways, such as 
the hypoxia-inducible factor (HIF) pathway.139-141 Researchers have studied 
preconditioning cells with hypoxic conditions and observed that acclimating the cells to 
the harsh conditions before abruptly implanting them into ischemic tissue enhanced 
therapeutic results.142-144 The goal of this work was to develop an in vivo platform that will 
ease the extent of hypoxia faced by implanted stem cells. Consequently, this will allow 
implanted cells to better adapt and survive the ischemic conditions and lead to improved 
therapeutic effects. 
The developed platform consists of a hydrogel stem cell delivery vehicle doped 
with laser-activated PFCnDs. PFC compounds have been extensively used in the medical 
field as oxygen carriers because they are inert and can solubilize high amounts of gases.51, 
145-146 Due to the nature of PFC oxygen loading and delivery, PFCs do not possess any of 
the cytotoxic byproducts associated with peroxide-based oxygen delivering 
 64 
biomaterials.136, 147 The degree of gas solubility in PFCs follows Henry’s law, with higher 
solubility at increased pressures.53 Thus, PFCnDs can be synthesized with high oxygen 
payloads within their highly pressurized, perfluorocarbon liquid core.8 Additionally, 
PFCnDs can be triggered to act as photoacoustic and ultrasound contrast agents, providing 
image-guided oxygen delivery. Encapsulation of a photoabsorber within PFCnDs, 
followed by pulsed laser irradiation, will cause PFCnDs to undergo a phase change that 
produces an intense photoacoustic signal and ultrasound enhancement.4, 34 The platform 
takes advantage of PFCnDs’s oxygen carrying and ‘activatable’ image contrast 
characteristics to deliver oxygen via two mechanisms:  1) passive diffusion or 2) activated 
release via laser irradiation of PFCnDs. The first, passive diffusion, is a function of the 
PFCnD shell and the surrounding medium’s oxygenation.148-149 Activated release occurs 
when laser irradiation initiates PFCnD phase-change which compromises the membrane 
and facilitates escape of encapsulated oxygen. The novelty of the system is the activated 
release component that allows for on-demand, image-guided release. This feature enables 
future development of personalized treatment options that can vary based on the patient’s 
ischemic injury severity. To demonstrate the platform’s utility, I first investigated the 
optimal PFCnD loading concentration and confirmed the system’s ability to mitigate 
hypoxic conditions. I further examined the effects of oxygenated PFCnDs on cell viability 
and on a protein regulated by oxygen availability, intracellular HIF-1α. Lastly, I 
demonstrated the image-guided release of oxygen in solutions and in hydrogels. As PFCnD 
technology continues to advance, the designed platform will bring increased control over 
oxygen delivery; potentially making it a useful method of personalizing treatments and 
helping bring stem cell angiogenic therapies closer to clinical utility.  
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 Materials and Methods 
5.2.1 Synthesis and characterization of PFCnDs 
PFCnDs were synthesized with a bovine serum albumin (BSA) shell, similar to 
previously published work.4 Briefly, a BSA saline solution (3 mg/ml) was prepared. 200 
µl of perfluorocarbon (either perfluoropentane or perfluorohexane) were added to 1 mL of 
the BSA solution. To make laser-activated PFCnDs, a 1064 nm absorbing dye (Epolight 
3072, Epolight Inc.) was added as the photoabsorber. The mixture was briefly vortexed 
and then sonicated in an ice-cold water bath sonicator (VWR, 180 W) until the solution 
became milky and no remaining perfluorocarbon bolus was observed. To fabricate 
oxygenated PFCnDs, the solution of PFCnDs was purged with oxygen (flow rate 2 L/min) 
for 2 minutes.   Following synthesis, a 1:100 dilution of PFCnDs in DI H2O was prepared 
and the hydrodynamic size and zeta potential were studied in a Zetasizer Nano ZS 
(Malvern). A 1:1000 dilution of PFCnDs in DI H2O was prepared and a Nanosight NS300 
(Malvern) used to determine PFCnD concentration. 
In studies requiring fluorescently labeled PFCnDs, particles were formed with a 
lipid shell and lipophilic dye, DiI. Briefly, 3 µl of DiI (3 mg/ml; ThermoFisher) in 
chloroform was mixed with, 100 µl of the photoabsorber (1 mg/ml, Epolight 3072; 
Epolight Inc) and 20 µl of 1,2- distearoyl-sn-glycero-3-phosphocholine (DSPC, 10 mg/mL; 
NanoCS Inc.) lipid in chloroform, and placed in a 50 mL pear shaped flask. A rotovap 
(Bunchii) was used to evaporate off the chloroform and then 1 mL of PBS was added to 
rehydrate the lipid cake.  75 µl of perfluorohexane was added and sonicated to produce the 
droplets. 
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5.2.2 Stem cell culture 
Human adipose stem cells (hASCs) were purchased from Lonza (Walkersville, 
MD). Cells were cultures in Dulbercco’s Modified Eagle Medium (DMEM) (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 1% glutamax, and 1% 
penicillin-streptomycin. All cells utilized in subsequent studies were passages 3-7. 
5.2.3 Fabrication of PFCnD hydrogel scaffolds 
Human fibrinogen was dissolved in PBS (without calcium, pH 7.8) at a 
concentration of 80 mg/ml. Succinimidyl glutarate-modified polyethylene glycol (PEG; 
NOF America) was similarly dissolved in DPBS at 8 mg/ml. The two solutions were mixed 
in a 1:1 volume ratio for 10 minutes to allow for PEGylation of fibrinogen. A specific 
concentration of PFCnDs in PBS (without calcium, pH 7.8) was prepared (either no nDs, 
106 nD/ml, 108 nD/ml, 109 nD/ml, 1010 nD/ml, or 1012 nD/ml) and added to the PEG-
fibrinogen solution at a 1:1 volume ratio. In cases where hASCs were incorporated into the 
hydrogel, hASCs were added into the PFCnD-PBS component to have a final concentration 
of 1×105 cells/ml.  Then, an equal volume of human thrombin (25 U/ml in 40 mM CaCl2) 
was added for enzymatic crosslinking. The solution was placed in a 5% CO2 incubator at 
37°C to complete gelation. After gelation, DMEM media was added. For assays involving 
hydrogels removal, samples were prepared in well-plate inserts (BD Biosciences) for easy 




5.2.4 PFCnD concentration effect  
Different concentrations of PFCnDs were incorporated into hydrogels to determine 
their effect on cells.  The hydrogels, with incorporated hASCs, were placed in a cell 
incubator for 48 hours.  Cell viability and phenotype were assessed using an MTS 
proliferation assay and LIVE/DEAD staining, respectively. The MTS assay was performed 
by incubating phenol-free DMEM media containing 20% MTS solution at 37°C. After 
three hours, the supernatant was collected and a plate reader (Synergy HT, Biotek) was 
used to measure the absorbance at 490 nm (n =3). A blank sample’s, i.e. no cells, reading 
was subtracted from all measurements. For LIVE/DEAD staining, an equal volume of the 
prepared staining solution was added to the hydrogels for one hour. The hydrogels were 
washed with PBS several times, fixed with 10% formalin, and imaged using a Zeiss LSM 
700 confocal microscope. 
To study the effect of PFCnD concentration on hydrogel integrity, hydrogels were 
synthesized with differing PFCnD concentrations (no hASCs incorporated) and placed in 
a cell incubator. After 48 hours, the hydrogels were removed and individually weighed (n 
= 3).  
5.2.5 HIF-1α study 
HIF-1α studies were conducted in 2-D samples to study the influence of oxygenated 
PFCnDs and minimize the distortion of the additional hypoxia caused by the 3-D 
hydrogel.150 HIF-1α levels were compared between normoxic samples and ischemic 
samples supplemented with or without oxygenated PFCnDs. A cell incubator (Heracell 
VIOS 160i, ThermoFisher) set at 1% O2, 5% CO2 and DMEM supplemented with 1% FBS 
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were used to mimic ischemic tissue conditions. A concentration of 1x108 oxygenated 
PFCnDs/ml was added to the media for the test group. For the normoxic group, cells were 
placed in an incubator set at 20% O2, 5% CO2 and given DMEM with 10% FBS. hASCs 
were plated in 6-well plates and placed in the appropriate incubator for six hours. One hour 
before study completion, a proteasome inhibitor (MG132, Cayman Chemical) was added 
to minimize HIF-1α degradation. Cells were taken out and placed on ice and were lysed 
with a RIPA lysis buffer (RIPA, Santa Cruz) to extract HIF-1α. The samples were 
centrifuged and supernatant collected and used to run a HIF-1α ELISA (Lot#: 
KQE0414071; R&D Systems). The HIF-1α concentration was normalized to total DNA 
concentration measured by absorbance at 260 nm (Synergy HT, Biotek).  
5.2.6 Hypoxia cell viability study 
hASCs were incorporated in PEG-fibrin hydrogels and their corresponding test 
groups (no PFCnDs, oxygenated-PFCnDs). Groups were placed in normoxic (20% O2, 
regular media) or ischemic (1% O2, low serum media) conditions for 48 and 72 hours. At 
the specified time-point, hydrogels were taken out and the cell viability assessed using a 
LIVE/DEAD stain. Five random areas were imaged from each gel (n = 3) and the ratio of 
live to dead cells quantified using ImageJ.  
5.2.7 Oxygenation-lasing and imaging study  
A sealed chamber was used for simultaneously measuring a solution’s oxygen levels and 
obtaining photoacoustic data. The front face of the chamber had an optical window to allow 
for laser irradiation of the samples. The chamber had one inlet on the side to allow for 
nitrogen purging of the solution. Two additional inlets on the top, with rubber stoppers in 
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them, were designed to tightly introduce the oxygen probe or the sample.  The oxygen 
probe (NeoFox; Ocean Optics) was pierced through the rubber stopper and its tip placed in 
the headspace of the container. The other rubber stopper allowed for sample introduction. 
On one side of the chamber, a space was machined out and a 20 MHz transducer was placed 
in and sealed with silicone. This allowed for photoacoustic imaging with the Vevo imaging 
system (VisualSonics). 30 mls of DI H2O were added into the chamber and purged with 
N2. A stir bar was placed in the chamber for mixing throughout the experiment. After 
several minutes, oxygen measurements verified that O2 was sufficiently low and the N2 
supply was stopped and the chamber sealed shut.  Before starting the experiment, oxygen 
levels were allowed to reach a stable reading. 900 µl of oxygenated-PFCnDs were 
introduced into the chamber and the recording of oxygen partial pressure (ppO2) levels and 
photoacoustic data started. At one minute, the sample was irradiated with a 10 Hz pulsed 
laser at 1064 nm and a fluence of 50 mJ/cm2 (Vibrant, Opotek).  After 15 seconds the laser 
was turned off. Recording of ppO2 and photoacoustic data was stopped after a total time of 
two minutes. The same parameters were used for the control group, DI H2O.  
5.2.8 Imaging of activation event within hydrogel  
In addition to imaging the release of oxygen from PFCnDs in solutions, the ability 
to activate and image PFCnDs (perfluorohexane core) within a hydrogel was studied. The 
hydrogel was synthesized with one region containing PFCnDs with a photoabsorber and 
the other section had PFCnDs with no photoabsorber. A hydrogel region with both sample 
types was irradiated with 1064 nm, 10 Hz pulsed laser light at 40 mJ/cm2 (Vibrant, Opotek) 
and imaged with a 20 MHz transducer and VEVO imaging system. The collected data was 
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processed to identify and highlight the locations of activated PFCnDs according to a 
previously described algorithm.47 
5.2.9 Activation event on gel structure and ASC viability and gel structure 
The effect of activating PFCnDs on stem cells and hydrogel properties was studied 
with lipid shelled PFCnDs and an incorporated lipophilic fluorescent dye. The fluorophore, 
DiI, allowed for studying the PFCnD dynamics post-irradiation. Three µLs of DiI (3 
mg/mL; ThermoFisher) in chloroform was mixed with, 100 µLs of the photoabsorber (1 
mg/mL, Epolight 3072; Epolin Inc.) and 20 µLs of 1,2- distearoyl-sn-glycero-3-
phosphocholine (DSPC, 10 mg/mL; NanoCS Inc.) lipid in chloroform, and placed in a 50 
mL pear shaped flask. A rotovap (Bunchii) was used to evaporate off the chloroform and 
then 1 mL of PBS was added to rehydrate the lipid cake. A volume of 75 µLs of 
perfluorohexane was added and sonicated to produce the droplets. Hydrogels were 
synthesized with incorporated cells and PFCnDs and then placed in a cell incubator. After 
24 hours, samples were taken out and irradiated with 1064 nm pulsed laser at an energy of 
40 mJ/cm2 (Opotek Vibrant) for 30 seconds. Samples were replaced with new media and 
put in a cell incubator. For qualitative analysis, LIVE/DEAD staining was performed at 24 
and 48 hours post-lasing. Samples were taken out and stained with LIVE/DEAD stain. The 
gels were fixed with 10% formalin and then imaged on a Zeiss 700 confocal microscope.  
For quantitative comparison, MTS assays (n=4) were conducted at 24 and 48 hours after 




5.2.10 Statistical Analysis  
All data is presented as mean +/- standard deviation. Statistical significance was 
calculated by performing a one-way ANOVA analysis, followed by Tukey’s multiple 





5.3.1 PFCnD characterization  
A PFCnD emulsion were formed after sonication of the PFC, BSA and PBS 
mixture. The zeta potential of PFCnDs was -30.3 mV, indicating the colloidal stability. The 
hydrodynamic size of PFCnDs was measured to be approximately 400 nm (Figure 19a).  
 
Figure 19. (a) PFCnD size distribution was measured by DLS and found to be 400 nm. 
The insert shows the PFCnD emulsion following sonication. (b) A PEGylated fibrin 
hydrogel with and without incorporated PFCnDs. Incorporation of PFCnDs makes the gels 
less transparent but at the appropriate concentration does not affect hydrogel properties. (c) 
Schematic of the hydrogel with PFCnDs (green) and stem cells incorporated. 
5.3.2 Optimal PFCnD concentration  
Incorporation of PFCnDs into the typically transparent PEGylated fibrin hydrogel 
turned it more opaque (Figure 19b).  Increasing PFCnD concentration past 109 nDs/mL 
began led to faster hydrogel degradation (Figure 20a). Interestingly, the increased PFCnD 
concentration did not negatively impact cell viability. Instead, MTS results indicated that 
as the gel degraded, cells proliferated at an increased rate (Figure 20b). Increased cell 
proliferation was a result of cells falling out of the degrading gel and growing on the 
preferred 2-D surface. Cells located within the gels exhibited similar phenotypes across all 
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concentrations (Figure 20c-h). It should be noted that the cells imaged at the 1x1012 nD/mL 
were located within a part of the hydrogel that remained structurally intact. A concentration 
of 1x109 nDs/mls was used for subsequent studies as it did not impact gel integrity or cell 











Figure 20. Effect of PFCnD concentration on gel integrity and cells. (a) At PFCnD 
concentrations above 109nDs/mL the gel began to significantly degrade. (b) There is no 
negative effect of increasing PFCnD concentration on cell viability and proliferation. 
However, at the highest concentration many cells are growing on the 2-D surface instead 
of within the hydrogel, leading to the increased proliferation. (c-h) Cells imaged within the 
hydrogel are able to spread and exhibit the typical phenotype regardless of PFCnD 










5.3.3 Oxygenated-PFCnD influence on stem cells under hypoxia 
Cells cultured in ischemic conditions had significantly elevated levels of HIF-1α. 
However, in the ischemic group containing oxygenated-PFCnDs, HIF-1α expression was 
comparable to cells cultured in normoxia (Figure 21a) and significantly lower than cells 
cultured without oxygenated-PFCnDs. This demonstrates that PFCnDs can deliver enough 
oxygen to regulate HIF-1α degradation, resulting in a reduced expression.  
Oxygenated PFCnDs can influence cell viability for at least 3 days. At 48 hours 
there was no significant difference in cell viability amongst the three groups. However, at 
72 hours the hypoxia group with no PFCnDs had significantly reduced cell viability, while 




Figure 21. (a) Inclusion of oxygenated-PFCnDs (O2-nDs) results in lower HIF-1α levels 
which are similar to expression seen in cells cultured in normoxic conditions. Cells cultured 
in hypoxia with no PFCnDs had significantly elevated levels of HIF-1α compared to both 
normoxia and the O2-PFCnD group at 6 hours. (b) For cells are cultured in ischemic 
conditions, O2-PFCnDs significantly improve viability over cells without PFCnDs for up 






5.3.4 Activated oxygen release 
In addition to passive oxygen diffusion, increased payloads of oxygen can be 
delivered via laser irradiation of PFCnDs. The inclusion of oxygenated PFCnDs increased 
ppO2 immediately, indicating the occurrence of passive oxygen release (Figure 22b). Upon 
laser irradiation, there was an immediate increase in photoacoustic signal (Figure 22b,d). 
Shortly after, ppO2 increased by 5% (Figure 22b). When lasing was stopped, oxygen levels 
fell to a level slightly higher than before lasing and continued to gradually rise as before. 




Figure 22. (a) Experimental set-up for measuring ppO2 levels and capturing photoacoustic 
data. b. Upon lasing, oxygenated-PFCnDs oxygen levels increase, accompanied by a stark 
increase in photoacoustic signal. (c,d) The photoacoustic signal upon laser irradiation is 





5.3.5 Image-guided activation effects   
Different subsets of PFCnDs can be selectively activated and imaged to show the 
locations of activation. Laser irradiation of a hydrogel, no cells, containing either blank or 
photoabsorber-loaded PFCnDs causes activation only in the region containing the 
photoabsorber-loaded PFCnDs. The collected data can be image processed to clearly 
indicate regions of PFCnD activation (Figure 23a).  
When cells are included within the hydrogels, PFCnD activation and the subsequent 
expansion did not cause cell death in the short-term. Laser irradiation of PFCnD loaded 
hydrogels altered the gel’s structure creating a spongy effect in regions that had been 
irradiated. However, at 24 hours, MTS results showed that all groups had similar numbers 
of viable cells. Additionally, LIVE/DEAD staining confirmed there were many viable cells 
that were growing around the expanding cavities of the hydrogel (Figure 23b). At 48 hours, 
confocal images showed that the created pore’s size increased as more gas diffused into 
the cavities. MTS results indicated that the activated group had slightly lower, but 
insignificantly different cell viability and proliferation. The extent of PFCnD activation on 
cell viability is affected by the concentration of PFCnDs within the hydrogel. At higher 
concentrations, 1x1010 nD/mL,  there are more created cavities which significantly hinders 




Figure 23. (a) Image-processed ultrasound data of a hydrogel depicting how PFCnD 
activation can be controlled to one region. Red outline indicated the gel region with 
PFCnDs containing a photoabsorber, while the area to the left contains PFCnDs with no 
photoabsorber. (b) 24 and (c) 48 hours after laser irradiation cavities are created (purple 
dye is DiI present in the PFCnD shell). The cells remain viable and continue to spread at 
24 hours, but are more limited by 48 hours (LIVE/DEAD stain). (d,e) The concentration 
of PFCnDs effects cell proliferation after lasing due to the higher amount created cavities. 








Laser-activated PFCnDs present a unique method of improving stem cell 
angiogenic therapy efficacy. PFC-based particles have been studied in different biomaterial 
based applications to improve therapeutic outcomes because of their superior oxygen 
solubility and delivery.139, 151 Here, I demonstrate that in addition to PFCnDs passively 
influencing oxygen levels, they can release oxygen in an on-demand, image-guided 
process. The innovative platform uses laser-activated PFCnDs to control and localize 
oxygen release.  
At appropriate concentrations, PFCnD incorporation into the stem cell delivery 
vehicle did not affect cell viability. No cell toxicity was observed at any of the 
concentrations tested; likely in part a result of using a protein emulsifier versus another 
surfactant.152 While high PFCnD concentrations did not impact cell viability, 
concentrations above 109 nDs/mL did affect the hydrogel’s mechanical properties. This is 
partly due to the high concentration of emulsifier associated with increased PFCnD 
incorporation, compromising the integrity of the hydrogel and leading to faster 
degradation.153 Additionally, the high density of PFC, two times denser than water, 
combined with their high concentration could be too much weight for the hydrogel to bear, 
resulting in mechanical damage over time.63 Hence, while higher concentrations of 
PFCnDs would be beneficial for carrying increased oxygen payloads, there is a threshold 
beyond which premature hydrogel degradation would occur and negatively impact cell 
engraftment.  
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PFCnDs are effective at delivering oxygen and reducing the extent of hypoxia 
experienced by newly implanted stem cells. Cells cultured in 1% oxygen, but supplemented 
with oxygenated PFCnDs, demonstrate comparable HIF-1α levels to cells cultured in 
normoxia. HIF-1α is an important transcription factor related to cell survival and 
angiogenic response. Its levels are inversely related to the amount of oxygen available, as 
it is degraded through a process dependent on oxygen.154 Since HIF-1α levels peak at six 
hours following hypoxia exposure,155 this represents an ideal time-point for studying 
PFCnDs’s short-term influence. At this time point, oxygenated PFCnDs brought HIF-1α 
levels similar to cells cultured in normoxia. Additionally, oxygenated-PFCnDs have an 
impact on cell viability for up to 72 hours, which is in line with what others have 
observed.153  While the ideal scenario would be to have sustained oxygen delivery until 
blood vessel in-growth occurs (typically around day 14), 63, 136  the fact that the designed 
system can mitigate the hypoxia experienced by newly implanted cells and give them time 
to adjust, could have drastic implications on overall angiogenic efficacy. Another aspect to 
consider is the delicate balance between too much oxygen, which prevents production of 
angiogenic factors, and too little oxygen, which leads to stem cell death and limits 
therapeutic outcome.144, 156 To improve therapeutic outcome, stem cells must express some 
levels of HIF-1α in order to better survive, upregulate angiogenic factors, and exhibit their 
paracrine effects.135, 140 Considering that PFCnDs influence HIF-1α short-term (6 hours) 
and increase viability for up to 72 hours suggests that they can minimize apoptosis, while 
still promoting their angiogenic response over time. Speculating, it is possible that 
oxygenated PFCnDs could help condition newly implanted stem cells in situ, in a manner 
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similar to how in vitro pre-hypoxia conditioning works.142 In the future this must be tested 
with in vivo ischemic models.  
The capability of PFCnDs to release increased amounts of oxygen upon laser 
irradiation, and to localize the oxygen’s release with photoacoustic imaging augments the 
potential of previously studied perfluorocarbon-based oxygen delivery biomaterials 
(extensively reviewed in Farris et al.136). Additionally, the same photoacoustic and 
ultrasound imaging system needed to activate and visualize PFCnDs can be used to 
elucidate which tissues are severely hypoxic by studying deoxygenated and oxygenated 
hemoglobin levels.26, 65 With this knowledge, PFCnDs located in more hypoxic regions can 
be irradiated and release oxygen in areas of greater need. Hence, the developed system can 
help provide patient-specific treatments for increased efficacy. Currently, this idea is 
limited by the extensive passive release of oxygen from PFCnDs. The development of 
shells that reduce permeability may help retain oxygen within the core and allow for better 
control of its release upon laser irradiation.63  
Laser irradiation of PFCnDs within hydrogels does not result in cell apoptosis, but 
does alter the material properties over time. Fabilli et al. characterized a similar system 
and observed comparable phenomena.11, 157-158 Their system involves PFCnD-doped 
hydrogels; however, instead of laser-activation of PFCnDs they employ acoustic-
activation. This type of activation involves irradiating samples with peak rarefactional 
pressures (negative pressures) at a threshold that induces vaporization of PFCnDs.5, 157 At 
large enough negative pressures, acoustic activation can cause inertial cavitation of the 
PFCnDs and result in cell apoptosis.11 In contrast, the laser-activated PFCnD system did 
not result in any cell apoptosis (Figure 23d), suggesting that laser-activation successfully 
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induces phase change, but likely does not cause inertial cavitation. Similar to laser-
activated PFCnD data, acoustic vaporization of PFCnD results in bubble formation in the 
hydrogel, and the created bubbles grow over time.158 Given the results of the created 
cavities surrounded by the lipid used in PFCnD synthesis, it is possible that the repeated 
expansion of the PFCnDs during laser irradiation deforms the hydrogel and produces a 
negative pressure in the PFCnDs’s vicinity. The resulting negative pressure alters the 
interfacial tension and stability of the PFCnDs causing them to transition into bubbles that 
gradually expand as dissolved gas diffuses into the PFC bubbles, because of their high gas 
solubility.51, 159 Fortunately, this phenomenon does not impact cell viability at the time 
points tested and with the appropriate PFCnD concentration (109 nDs/mL). However, at 
higher concentrations (1010 nDs/mL) cell proliferation was significantly reduced at 48 
hours. Given the time point at which cells are impacted, it is likely the expansion of the 
bubbles, not the activation, is what causes reduced cell proliferation. However, this effect 
might be mitigated in vivo where immune cell infiltration and clearance of PFC are at 
play.59, 160 Interestingly, previous studies showed creation of these bubbles enhanced blood 




  Laser-activated PFCnDs as diagnostics 
6.1.1 Conclusion Aim 1: CuS-PFCnDs enhanced  
The unique combination of CuS NPs and PFCnDs helps to overcome current laser-
activated PFCnD limitations. By using CuS NPs, which optically absorb in the second 
optical window, as the photoabsorber that initiates the phase-change, PFCnDs can be 
activated to provide contrast at increased penetration depths. Unlike other metallic particles 
that optically absorb in this region, CuS NPs have been shown to be biodegradable, and 
can be synthesized at small sizes for renal clearance, increasing their biocompatibility over 
comparable photoabsorbers.76 Considering that the long-term biocompatibility is a 
significant issue in assessing clinical feasibility, CuS NPs could facilitate laser-activated 
PFCnDs’s chances of overcoming this hurdle.  
6.1.2 Future Directions: CuS-PFCnDs 
6.1.2.1 Understanding laser-activated vaporization dynamics 
Up until now, the exact dynamics of laser-activated PFCnD phase vaporization are 
not well characterized. In acoustically-activated PFCnDs there have been studies showing 
vaporized PFCnDs becoming a stable MB, and others showing that first they over-expand, 
oscillating towards a stable size.39 Similarly, laser-activated PFCnDs might exhibit 
different behaviours  based on the photoabsorber or PFC core. A better understanding of 
the particle dynamics can allow for improved image processing techniques. 
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 Another area to investigate is the potential of laser-activated release to cause 
inertial cavitation. As of now, the majority of conducted studies result in a stable or 
transient microbubble, but do not cause microbubble collapse, i.e. inertial cavitation. In 
acoustically activated PFCnDs, acoustic parameters can be altered to cause stable or inertial 
cavitation.11 As these each have different biological effects, understanding how to exploit 
both mechanisms would be helpful in future development of laser-activated PFCnDs as 
therapeutics. 
6.1.2.2 Increasing extravasation 
The first area CuS-PFCnDs could have an impact on is as diagnostic agents. CuS-
PFCnDs’s increased imaging depth over comparable laser-activated PFCnDs expands their 
diagnostic abilities to deeper tissues. Upon appropriate functionalization, CuS-PFCnDs 
could act as effective diagnostic agents for vascular markers. However, if they are to be 
effective extravascular diagnostic agents, then they must be able to extravasate to the 
needed degree, a challenge facing all NPs. NP extravasation studies have shown that a very 
small amount (~1% of injected dose) is able to enter into solid tumors.45 Reducing the size 
and stealth (i.e. ability to evade RES system) of CuS-PFCnDs could improve extravasation. 
Using in vivo cancer models will help elucidate if meaningful amounts of CuS-PFCnDs 
can extravasate.  
6.1.2.3 Development of CuS-PFCnDs as therapeutic agents 
CuS NPs photothermal stability makes them well suited for photothermal therapy 
(PTT).75 PTT works by elevating the temperature of cancerous cells to levels that induce 
apoptosis. To accomplish this, a continuous wave laser tuned to the photoabsorber’s 
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absorption wavelength irradiates a tissue of interest and creates a localized temperature 
increase. The benefit of PTT is that it is very selective, only occurring at the irradiated 
tissue, and much more concentrated in areas containing photoabsorbers. Additionally, 
cancer cells have a reduced heat tolerance, making them more susceptible to PTT.162 In 
order for PTT to be effective, there needs to be increased concentrations of CuS NPs in the 
lesion combined with adequate laser exposure.75 Hence the previously mentioned 
extravasation limitation  will be a limiting factor in achieving effective PTT. However, 
conversion of CuS-PFCnDs into microbubbles, followed by high intensity ultrasound to 
cause inertial cavitation, could aid in increasing levels of CuS NPs delivery into the tumor. 
Previous work using CuS-MB have looked at achieving a similar effect, but have not yet 
demonstrated success in vivo.163   
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6.1.3 Conclusion Aim 2: Multiplexed imaging with multicolored PFCnDs 
The developed multicolored laser-activated PFCnD platform has potential in both 
diagnostic and therapeutic applications. In diagnostics, multiplexing capabilities are 
increasingly being investigated, particularly in cancer applications.98 Considering that 
biological specimens are often multifaceted, the ability for a diagnostic agent to convey the 
intricacies over a single modality will greatly impact diagnosis efficacy and efficiency. For 
instance, in breast cancers there are several subtypes, each with differing prognosis and 
treatment options. One of the most influential factors in deciding the course of treatment is 
that type or receptors present, i.e. hormone-positive/-negative and/or HER2-positive/-
negative.164 Additionally complicating the situation is that there are intratumor and 
intertumor (if metastasis has occurred) heterogeneities, and the fact that cell populations 
may change over the course of treatment.40 Currently, biopsies followed by an in vitro 
assay (ex: Immunohistochemistry or in situ hybridization) are used to guide treatment.164 
If multicolored PFCnDs can successfully reach their target, they would present a non-
invasive manner of conveying the necessary comprehensive pathological information, and 
because there is no ionizing radiation, they could also monitor therapeutic progress as 
repetitive imaging is not a concern.  
Studies using multicolored PFCnDs helped uncover that intradermal PFCnDs can 
successfully traffic to the lymph nodes and persist for several days, greatly increasing their 
potential therapeutic applications. Previous studies have only investigated short-term 
applications of PFCnDs. A better understanding of their stability and lifetime in vivo will 
lead to improved therapies. For instance, exhaustive and targeted treatments can be 
administered with a single dose of multicolored PFCnD, where each subpopulation carries 
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distinct therapeutics and releases them in a sequential, image-guided manner. One area that 
could benefit from this is next generation immunotherapies that are looking at 
combinations of therapeutics.165-166 One PFCnD subpopulation could be loaded with a 
targeted drug and another with an inhibitor, then laser-irradiation of the respective groups 
would allow for localized release. 
Overall, the described work advances PFCnD technology and establishes these 
particles as comprehensive diagnostic and therapeutic agents, but future work is crucial in 
demonstrating them as next generation diagnostic and therapeutic agents. 
6.1.4 Future Directions: Multiplexed PFCnDs  
6.1.4.1 Increase subpopulations of PFCnDs 
With the development of narrower absorption peak photoabsorbers, increased 
numbers of PFCnDs subpopulations can be synthesized for improved multiplexing 
capabilities. This will be of particular importance in cancers with various subtypes, i.e. 
breast cancer, where subtype dictates the needed treatment.167 Appropriate phantom studies 
should be conducted to demonstrate selective PFCnD activation and USPA response.  
6.1.4.2 Show ability to differentiate between different cell populations in vitro 
The ability of multicolored PFCnDs to detect different cancer subtypes should be 
demonstrated in vitro. This can be done by culturing different breast cancer cell lines at 
varying ratios, and adding equal amounts of differently functionalized PFCnDs (anti-
HER2, anti-ER, anti-EGFR, etc.) to the cells. After allowing for PFCnD-cell receptor 
interaction, the cells would be detached and fixed. Cell inclusion phantoms would be able 
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to demonstrate if photoacoustic signal at subpopulation wavelengths correlate to cultured 
cell ratios. 
6.1.4.3 Diagnosis of solid tumors 
As with CuS-PFCnDs, multicolored PFCnDs must be able to enter into solid tumors 
to successfully diagnose cancer subtype. Systemic and intratumor injections should both 
be studied and their diagnostic potential assessed. In the case of intratumor injections, 
multicolored PFCnDs would be beneficial because one of the subpopulations can be used 
as a baseline indicator to normalize signal for other subpopulations. This would help reduce 
any off-target associated signals that arise due to PFCnD retention at the injection site. For 
systemic injections, improving extravasation will be key.  
6.1.4.4 Increasing extravasation of PFCnDs 
Multicolored nanodroplets could help overcome the hurdles associated with 
extravasation and penetration of NPs into solid tumors. One subpopulation of multicolored 
PFCnDs could be targeted to tumor endothelium (e.g. VEGFR-2). Upon phase-change, the 
pressure waves created by the vaporization event could increase vascular permeability. If 
needed, ultrasound could be applied to the produced microbubbles to further increase 
acoustic radiation forces and vascular permeability.163, 168 This would allow the other 
subpopulations to more readily enter into the tumor. Upon entry, laser-triggering of another 
PFCnD subpopulation in conjunction with ultrasound could be used to cause stable 
cavitation that increases tumor ECM permeability to facilitate penetration of the remaining 
PFCnDs. This pattern could be continued based on the amount of PFCnD subpopulations 
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available. The result would be more extensive tumor infiltration, which would improve 
current diagnostic and therapeutic outcomes.  
6.1.4.5 Sentinel lymph node detection 
The conducted lymph node studies indicated that PFCnDs traffic to tumor draining 
lymph nodes via cell-mediated trafficking. This is both advantageous and problematic. It 
could be problematic if PFCnDs are expected to diagnose metastatic sites, since they will 
not be able to interact with cancer cells from inside APCs. Studies with reduced PFCnD 
size, and increased stealth properties should be studied to determine their lymphatic 
trafficking mechanisms and ability to directly interact with cancerous cells at these sites. 
6.1.4.6 Multicolored PFCnDs as companion diagnostics 
If the aforementioned diagnostic hurdles are overcome, multicolored PFCnDs 
could serve as a companion diagnostic to predict a patient’s response to therapy and/or 
monitor their response overtime.  The Food and Drug Administration (FDA) defines 
companion diagnostics as a “device or imaging tool that provides information that is 
essential for the safe and effective use of a corresponding therapeutic product.”169 
Currently, there are over 30 companion diagnostics, but only one of them is an imaging 
tool (MRI based); the rest are in vitro tests.169-170 Given the low-cost, and safety (non-
ionizing radiation) of USPA, multicolored PFCnDs would be an attractive imaging tool for 
use as a companion diagnostic. Functionalized multicolored PFCnDs could noninvasively 
convey information regarding cancer receptor presence to dictate the appropriate treatment. 
Multicolored PFCnDs could also be used to monitor a patient’s response and adjust 
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treatment as needed.171 This is particularly useful given that tumor cell populations can 
evolve overtime as some cells become resistant to therapies172 
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 Laser-activated PFCnDs as image-guided oxygen therapeutics 
6.2.1 Conclusion Aim 3 
 Laser-activated PFCnDs advance the use of perfluorocarbon-doped hydrogels 
through image-guided oxygen release. Upon laser irradiation the PFCnDs undergo a phase-
change, which compromises the shell membrane and causes increased oxygen release. This 
event can be localized with ultrasound and/or photoacoustic imaging techniques to show 
where higher payloads of oxygen were delivered. In addition, laser-activated PFCnDs, like 
its predecessors, can passively deliver sufficient levels of oxygen to alleviate the hypoxic 
implantation site and mitigate cell apoptosis. In vitro studies demonstrate that oxygenated 
PFCnDs reduce hypoxic protein expression and increase cell viability short-term, 
demonstrating their potential to mitigate the sudden hypoxia experienced by cells post-
implantation. As PFC-based technologies continue to advance, the presented platform 
could be used for tailoring stem cell angiogenic therapies for increased efficacy. 
6.2.2 Future Work 
6.2.2.1 Increase control of oxygen delivery  
One significant limitation of PFCnDs for oxygen delivery is the lack of control due 
to extensive passive release. Oxygen release out of oxygen-permeable PFCnD shells is 
dictated by Henry’s law, i.e. dependent on partial pressure of oxygen. Therefore, when 
oxygenated PFCnDs are introduced to a hypoxic environment, the carried oxygen will 
immediately begin to be diffuse out of the PFCnDs core.149 Groups have engineered shells 
with increased rigidity and stability to limit oxygen diffusion, but still observed rapid 
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release of oxygen when PFCps are placed in hypoxic conditions.173 Although the diffusion 
rate is reduced in the hydrogel environment, compared to liquid, it still occurs faster than 
preferred.174 
One clear benefit of externally-triggering oxygen release is there is no dependence 
on shells to exhibit any degree of oxygen permeability. This is in contrast to many groups 
who try to minimize passive diffusion, but must still rely on it to increase oxygen levels 
overtime.63 Thus, thicker, denser shells that significantly impede oxygen release can be 
employed for laser-triggered PFCnDs. The only requirement is that laser-activated 
vaporization must still be able to occur. Studies focused on the aforementioned shell 
parameters would greatly impact laser-activated PFCnDs’s role in controlling oxygen 
delivery. 
6.2.2.2 Show efficacy in in vitro ischemic models 
PFCnDs have shown the ability to alleviate hypoxic conditions short-term, i.e. up 
to 3 days.  The extent of current PFCnD-based oxygen delivery may be enough to act 
analogously to pre-conditioning cells with hypoxia, particularly considering when cells 
pre-conditioned with hypoxia for only 24 hours exhibited beneficial tissue healing effects 
in vivo.132 One advantage of using PFCnDs to alleviate hypoxia for cells in situ, is the 
reduction in time needed prior to cell implantation, i.e. no reliance on cell treatments 
beforehand. The impact of the described short-term benefits could be further 
complemented in vivo, where other cells, such as macrophages, contribute to tissue 
regeneration and remodelling.175 An in vivo hind limb ischemia model will help verify the 
suspected impact oxygenated PFCnDs can have in stem cell angiogenic therapies. 
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6.2.2.3 Post-PFCnD activation events on tissue in growth and stem cell fate 
Activation of PFCnDs within the hydrogel resulted in bubble formation which grew 
overtime, creating a sponge-like hydrogel. Fabilli et. al. demonstrated that acoustically 
activated PFCnD doped gels underwent the same hydrogel deformations seen with our 
model. Interestingly, in in vivo models they observed higher vessel in-growth in hydrogels 
that exhibited the sponge-like effect compared to controls. It is hypothesized that inclusion 
of PFCnDs increases oxygen, and the ability of cells to invade the hydrogel, which 
subsequently led to increased vessel in-growth.161 Considering that these studies did not 
include highly oxygenated-PFCnDs, further beneficial effects on blood vessel in-growth 
could be seen by incorporating this type of PFCnD. Once again, in vivo studies will help 
confirm this hypothesis.  
In addition to a passive influence, the creation of bubbles within the hydrogel can 
be externally manipulated to alter stem cell fate. It is well established that stem cells 
respond to environmental cues in the form of both chemical and physical stimuli.176 After 
laser-triggered activation has produced bubbles within the hydrogel, ultrasound can be 
administered to oscillate the created bubbles, thereby exerting forces (tensile and 
compressive) onto surrounding cells. The impact of these forces in directing stem cell 
differentiation should be studied in controlled, in vitro models. 
6.2.2.4 Oxygen delivery in cancer applications 
Apart from stem cell angiogenic therapies, the developed technology could not only 
be relevant for other stem cell therapies, but also for cancer applications. Increased tumor 
hypoxia is correlated with tumor progression, malignancy and resistance to therapy.177 
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Reducing hypoxia, through oxygen delivery to tumor sites, can increase susceptibility of 
cancer cells to radiation-based therapy.65 Light-triggered PFCnDs would be particularly 
advantageous for these applications due to the platform’s use of photoacoustic imaging 
which can simultaneously assess tissue hypoxia and localize oxygen release of PFCnDs.  
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 Overall Conclusion and Future Outlook 
The accomplished work successfully bridged some of the current gaps associated 
with laser-activated PFCnDs, better positioning them as attractive diagnostic and 
therapeutic agents. In terms of their utility as diagnostic agents, I developed PFCnDs that 
exhibit increased imaging depth, stability and biocompatibility characteristics. 
Additionally, the created multiplexed platform established laser-activated PFCnDs as next 
generation diagnostic agents. It also helped uncover valuable functional information that 
will be of importance for future uses of PFCnDs as both diagnostics and therapeutic agents. 
Furthermore, I demonstrated that laser-activated PFCnDs can be used for image-guided 
therapy delivery, specifically of oxygen. However, limitations regarding excessive passive 
release from oxygenated-PFCnDs must be addressed for higher controllability and 
effectiveness. As is, PFCnDs can alleviate hypoxic conditions faced by stem cells short-
term, and alter hydrogels in a manner that should allow for enhanced in vivo integration.  
Future work will continue to build upon these advancements and hope to establish 
laser-activated PFCnDs for clinical use. The advances achieved in this dissertation will 





A.1  Introduction 
Chapters 3 and 4 focus on enhancing PFCnDs’s diagnostic agent abilities. One topic 
discussed in both chapters is the background-free imaging ability of PFCnDs. This is 
accomplished using a developed algorithm that distinguishes PFCnDs’s distinct ultrasound 
and photoacoustic temporal signal from intrinsic tissue signal. The following section 
provides a thorough explanation of the photoacoustic/ultrasound response of PFCnDs and 
the developed image processing techniques. 
The temporal photoacoustic and ultrasound signal signatures of PFCnDs depend on 
the perfluorocarbon core utilized, i.e. whether the PFCnD exhibits a single or repeatable 
vaporization. The conducted diagnostic agent studies of PFCnDs all use perfluoropentane 
(boiling point: 29ºC) as a core, resulting in a one-time vaporization event. By observing 
the trends in photoacoustic or ultrasound signal overtime, it is possible to discriminate 
laser-triggered PFCnDs from endogenous signal. 
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A.2  Methods 
A.2.1 Synthesis of PFCnDs 
PFCnDs were synthesized with a lipid shell and encapsulated 1064 nm 
photoabsorber via water bath sonication (see 4.2.1 for complete description).  
A.2.2 USPA Imaging 
All imaging experiments were conducted using a 40-MHz ultrasound and 
photoacoustic imaging probe (LZ-550, Visualsonics Inc.) coupled to a combined 
ultrasound and photoacoustic imaging system (Vevo LAZR, Visualsonics Inc). The laser 
operated at 1064 nm wavelength producing 5-7 ns laser pulses at 20-Hz pulse repetition 
rate. The fluence was measured to be between 6-9 mJ·cm-2. 
A.2.3 In vivo imaging 
Studies conducted adhered to approved protocols by the Institutional Animal Care 
and Use Committee at Georgia Institute of Technology. Mice (nu/nu) were anesthetized 
using a combination of isoflurane (1.5-2.5%) and O2 (0.8 Lmin
-1) and placed on an animal 
heating pad, regulated at 37°C, during imaging.  Mice were intravenously injected with 
150 µl of stock PFCnDs through the jugular vein. After sufficient time, the spleen was 
localized and imaged at 1064 nm. Ultrasound B-mode and photoacoustic images were 





A.3.1 Photoacoustic-based background-free images 
Upon laser induced PFCnD vaporization, there is an intense photoacoustic signal. In 
stationary samples, the signal is at a maximum immediately after the laser pulse that causes 
vaporization, which is typically the first laser pulse, and then decreases overtime (Figure 
24). The rate at which it decreases is dependent on the PFCnD portion that is vaporized 
compared to the total that are vaporized throughout the imaging period. If the entire PFCnD 
population in the region of interest is vaporized after the first laser pulse, then the maximum 
photoacoustic is large and the drop in photoacoustic signal is drastic. If some unvaporized 
PFCnDs remain, or subsequently enter the image plane, and are vaporized on ensuing laser 
pulses, then the peak photoacoustic signal is reduced, and the decay is more gradual. When 
all vaporization events have occurred, the photoacoustic signal drops to a baseline level 
representative of the thermoelastic expansion of the photoabsorber utilized (Figure 24b). 
The difference between the maximum photoacoustic signal and the baseline photoacoustic 
signal is referred to as vaporization-associated photoacoustic signal. The larger the 
difference, the more effective the photoabsorber is at initiating PFCnD vaporization.  
Background-free imaging through localization of PFCnDs is extremely 
advantageous because of the endogenous photoacoustic signal seen at many wavelengths. 
Even at 1064 nm, which is within the optical window, there is still endogenous signal 
(Figure 24a). To localize vaporized PFCnDs, pixels with a rapidly decreasing 
photoacoustic signal were identified via image processing using MATLAB. For the 
technique to effectively work, it is important to image for a significant time frame in order 
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to capture both the decay and baseline PFCnD temporal pattern. Then, frames that capture 
the decay, but avoid frames depicting photoabsorber baseline signal, are selected (Figure 
24b, yellow dashed square) and pixel-wise linear regression is performed. Prior to the linear 
fit, undesired sample motion can be accounted for by applying a spatial averaging window 
in spatial (X-Y plane) and time (Z) dimension. Once the linear fit is determined, the slopes 
from each pixel are extracted. The slopes indicate the change in photoacoustic signal over 
the studied time, therefore higher value slopes correlate to vaporized PFCnDs, while those 
with a slope closer to 0 indicate endogenous photoacoustic signal or noise (Figure 24b). A 
threshold value is selected to only display pixels that exhibit a large variation rate, i.e. 
indicative of vaporized PFCnDs. The identified pixels are then displayed over an 
ultrasound image for anatomical reference, resulting in a photoacoustic-based background-




Figure 24. (a) Unprocessed photoacoustic signal at several different time points during the 
irradiation sequence. (b) Temporal photoacoustic signals of pixels with PFCnD and 
endogenous signal. Linear regression is performed on frames that capture the decay. Slopes 
(-4.8 vs -0.38) with rates above a certain threshold are identified. (c) The result is a much 




A.3.2 Ultrasound-based background-free images 
The vaporization-related ultrasound signal of PFCnDs’s mirrors the photoacoustic 
signal, i.e. increases over time. After the vaporization initiating laser pulse, activated 
PFCnDs begin to transition into microbubbles. However, in order to provide effective 
ultrasound contrast enhancement, the created MB must first reach a minimum size. This is 
typically achieved at around 1 µm, depending on the imaging setup and processing 
available.2, 108 Consequently, the ultrasound enhancement is less immediate compared to 
the photoacoustic signal. Similar to photoacoustic signal, for stationary samples the rate of 
increase is associated with the portion of phase-changed PFCnDs at each laser pulse. Faster 
rates indicate efficient vaporization, whereas slower rates indicate more laser triggers were 
needed. After some time, the ultrasound signal reaches a maximum and plateaus (Figure 
25). 
Background-free ultrasound images are extremely useful for diagnostic applications 
as they provide a clear special map of PFCnD location. In an analogous method to 
photoacoustic signal processing, pixels with rapidly increasing ultrasound signal are 
identified. Frames that capture the ultrasound increase are selected for processing (Figure 
25b-yellow dashed square), and pixel-wise linear regression is performed. 
 Pixels which exhibit a slope above a certain threshold are identified as locations 
where microbubbles were created, i.e. PFCnD phase-change occurred (Figure 25). The 
selected pixels are displayed over an ultrasound image for anatomical reference, resulting 
in an ultrasound-based background-free image (Figure 25c).  
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Figure 25. (a) Ultrasound signal at several different time points during the irradiation 
sequence. (b) Temporal ultrasound signals of pixels with PFCnD and endogenous signal. 
Linear regression is performed on frames that capture the decay. Slopes (2.47 vs 0.28) with 
rates above a certain threshold are identified. (c) The processed image depicts location of 









A.4 Discussion  
One tremendous advantage of laser-activated PFCnDs is that they provide unique 
photoacoustic and ultrasound temporal contrast. This is significant because in vivo imaging 
will introduce endogenous signal and biological interaction that might affect PFCnD 
photoacoustic and/or ultrasound contrast. However, as along as one form of signal can be 
effectively processed, then background-free images can be formed. An additional benefit 
is that baseline imaging is not needed, as identifying vaporized PFCnDs can eliminate 
endogenous signal. 
In order to better understand the developed algorithms, and when one form of image 
contrast is better-suited compared to the other, certain in vivo scenarios are described 
below.  
A.4.1 Situations that result in reduced photoacoustic signal 
In cases of low concentration and slow flowing PFCnDs (see Chapter 3 Lymph Node 
example), the vaporization-associated photoacoustic signal is too weak to differentiate it 
from other endogenous signal. Additionally, due to optical scattering in tissue, PFCnDs 
outside the imaging plane may vaporize, effectively reducing the amount of PFCnDs 
providing photoacoustic signal in plane. This renders photoacoustic-based background-
free imaging unsuitable.  
The type of photoabsorber will also dictate how well photoacoustic-based signal 
processing will be. In instances where the vaporization event is not significantly more than 
its photoabsorber baseline (at least two times higher) then the processing algorithm will 
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struggle as the slopes between vaporizing pixels and endogenous signal will not be as 
different.  
A.4.2 Situations that result in reduced ultrasound signal 
In some situations, the phase-changed PFCnDs do not provide any or enough 
ultrasound signal to process. This can occur when the size of PFCnDs has greatly 
decreased, which can happen as PFC diffuses out of the PFCnDs. Since PFCnDs will 
expand 5 times their size upon vaporization, PFCnDs significantly smaller than 200 nm 
will produce bubbles of less than 1µm in size, which do not provide significant ultrasound 
enhancement. However, harmonic imaging and other imaging techniques may still be able 
to localize these smaller sub-micron bubbles.  
Another instance of reduced ultrasound signal can occur when PFCnDs are taken up 
by cells. Cells may selectively uptake PFCnDs of reduced size, which would inhibit their 
provided ultrasound contrast. Alternatively, cell uptake could affect the ability of created 
MBs to reach their full-size potential, once again diminishing their ultrasound contrast.  
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Adapted from: Directional conjugation of antibodies to nanoparticles for synthesis of 
multiplexed optical contrast agents with both delivery and targeting moieties. Nature 
Protocols (2008).101  
PFCnD preparation 
1) Add the following into a pear shaped rotovap flask (~50 ml size preferred): 
 9.4 µl of DPPC (10mg/ml) 
 7.4 µl of DSPE-PEG2kDa (25 mg/ml) 
 2.4 µl of –MAL (10 mg/mL)  
 100 µl of Epolight dye (1mg/ml) if making laser-activated nDs 
 2.0 ml of chloroform 
2) Using a Rotovap, slowly evaporate off the chloroform (i.e. slowly reduce P from its 
starting point) and spin at 200 RPM. Result should be a thin cake spread along the rotovap 
flask, if it does not look like a good lipid cake, you can add 2 more mls of chloroform and 
retry.  
3) Once lipid cake is dry (confirm dry with N2 purge if necessary), add 1 ml of PBS. Vortex 
and sonicate to resuspend all the lipid in PBS. 
4) Transfer solution to an 9 ml vial and add 75 µl of PFC 
5) Vortex and sonicate in COLD water (add ice to water bath) 






1) Antibody or antibodies (100ul at 1 mg/ml in PBS).  
2) Linker solution (46.5 mM): Prepared by dissolving 33 mg of dithiolaromatic PEG6-
CONHNH2 in 1 ml DIUF H2O). Can be approximated as long as it is in excess of the 
antibody concentration 
3) Purpald solution: 10 mg/ml Purpald dissolved in 1N NaOH (freshly prepared).  
4) 100 mM Na2HPO4 
5) 100mM NaIO4 [21.3 mg in 1 ml of DIUF H20] 
6) 1x PBS 
7) 40 mM HEPES 
Procedure 
Attaching linker to antibody 
1) Attach linker to antibody. Large batches of antibody-linker complex can be prepared 
and stored before nanoparticle conjugation. Dilute or resuspend antibody solution to 1 
mg/ml in 1 ml of 100mM Na2HPO4, pH 7.5. If antibody solution is more dilute than 1 
mg/ml, the solution will need to be concentrated and exchanged for 100mM 
Na2HPO4, pH 7.5.  
Our antibodies are 100 µg solutions. Therefore, for 1 mg/ml, or 1000 µg/ml 
it needs to be in 100 µl of Na2HPO4. 
 
2) Add 10 µl of 100 mM NaIO4 to 100 µl of 1 mg/ml antibody solution in 100 mM 
Na2HPO4. Incubate in the dark for 30 min at RT, 125 RPM agitation.  
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3) Quench the reaction with 500 µl of 1x PBS.  
4) Quality control: To verify the oxidation of the carbohydrate, add 15 µl drop of 
Purpald solution [freezer] onto parafilm. Add 5µl of antibody solution and mix. The 
solution should turn purple in a few minutes to indicate aldehyde presence.  
5) Add 2 µl of 46.5 mM linker solution, in ethanol, to the antibody solution and incubate 
for 1 hr. at RT while shaking, 125 RPM. 
6) Add 1 ml of 40 mM HEPES and filter w/ 10k filter at 2000 g at 4C until 75% through 
(~10 minutes) 
7) Resuspend in 40 mM HEPES to final volume of 1 ml and AB con centration at 100 
ug/ml. 
FINAL PRODUCT: Functionalized antibody with the thiol-terminated linker off the FC 
segment.  
PAUSE POINT: Antibody-linker solution can be kept at 4C for the recommended storage 
time for the specific antibody. Linker does not affect stability of the antibody.  
Conjugation to perfluorocarbon nanodroplets (adapted from Thermo Sci protocol “Attach 
an antibody onto glass, silica or quartz surface) 
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Attaching antibodies to PFCnDs 
 
1) Combine 20 µl of antibody-linker solution with 100 µl of PFCnDs in 900 µl PBS. 
Incubate for 1 hour at room temperature in the dark. Use rotator for mixing 125 
RPM.    
Note: For cell studies [PFCnD] is 106, stock is 1010 
2) Quality control: Use Plate reader to see if antibodies are present.  
3) A 100 µl of 10-5M 5 kDa mPEG-SH is used to backfill unreacted maleimide 
groups and left to incubate for 1 hour, room temperature 
4) Centrifuge at 900 rpm for 2 minutes to get rid of excess PEG and Abs 
 
In vitro cell studies 
Cells should be cultured on glass chamber slides for best results. Cell can be stained with 
Cell Tracker before PFCnD incubation. 
1) Add targeted PFCnDs (1:10000 dilution from stock, final should be ~106 nDs/ml 
2) Incubate for 1 to 2 hours in serum free media 
3) Aspirate particles and wash 5 times with PBS, being careful not to detach cells 
4) Fix cells with 10% Formalin for 10 minutes 
5) Wash with two times with PBS, ensure slide is sufficiently dry before proceeding. 
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